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1. Abstract 
The influenza virus hemagglutinin (HA) mediates viral entry into target cells. HA is 
synthesized as an inactive precursor and depends on proteolytic processing by host cell 
proteases to become active. TMPRSS2, a member of the type II transmembrane serine 
protease (TTSP) family, can cleave and activate HA in cell culture and was recently shown to 
be essential for spread and pathogenesis of influenza viruses of the H1N1 subtype in mice. In 
contrast, an H3N2 influenza virus was less dependent on TMPRSS2, implying that this virus 
may hijack other TTSPs for its activation. Moreover, studies with an animal coronavirus 
suggested that TMPRSS2 could impact virus infection at stages other than viral entry into 
cells. Therefore, the central goals of this thesis were: i) to identify TTSPs which activate HA; 
ii) to identify molecular determinants which control the ability of TTSPs to cleave and 
activate HA; iii) to determine whether TMPRSS2 promotes influenza virus infection by 
processes other than HA activation. 
The results of the present thesis show that DESC1 and MSPL, members of the TTSP 
family, activate diverse influenza viruses, while the related proteases TMPRSS11F, prostasin, 
TMPRSS11B, TMPRSS9 and TMPRSS10 fail to do so. Additionally, it was demonstrated 
that TTSPs which activate HA also colocalize with HA at or close to the cell membrane while 
this phenotype was not observed with enzymes unable to activate HA. Mutagenic analysis 
revealed that the stem region of TTSPs controlled their ability to colocalize and to activate 
HA. Moreover, evidence was obtained that targeting the scavenger receptor A domain present 
in the stem region of certain HA-activating TTSPs may block HA processing. Finally, 
evidence was obtained that TMPRSS2 and other HA-activating TTSPs can antagonize the 
antiviral host cell factor tetherin and might thereby promote influenza virus release form 
tetherin expressing cells. In sum, the present study identified two TTSPs as HA activators, 
and defined the stem region of TTSPs as a potential target for antiviral strategies. Finally, it 
was shown that TTSPs may promote influenza virus spread via two mechanisms, HA 
activation and tetherin inactivation. 
Keywords: influenza virus, hemagglutinin, type II transmembrane serine proteases, 
proteolytic cleavage, TMPRSS2, DESC1, MSPL, tetherin 
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2. Introduction 
Data from the World Health Organization (WHO) show that the main causes of global 
mortality are: i) ischemic heart disease, ii) stroke, iii) chronic obstructive pulmonary diseases, 
iv) respiratory tract infections, v) trachea, bronchus and lung cancer, vi) HIV/AIDS,  
vii) diarrheal diseases, viii) diabetes mellitus, ix) road injuries and x) hypertensive heart 
diseases (www.who.int, 2015). Respiratory tract infections were responsible for 3.1 million 
deaths (5% of total deaths) worldwide in 2012, with influenza being responsible for 
approximately 20% of these death (www.who.int, 2015). However, it should be underlined 
that the numbers differ between low- and high-income countries. In low-income countries, 
for instance Afghanistan and Kenya, lower respiratory tract infections were the main cause of 
death, killing 91 persons per 100,000 population. In contrast, in high income countries like 
Germany or the United States of America (USA), the main cause of death was ischemic heart 
disease and lower respiratory infections were responsible for the death of less than 31 persons 
per 100,000 population (www.who.int, 2015). Additionally, it should be underlined that 
influenza has a significant socio-economic impact, and causes high financial loss. 
2.1 Influenza – respiratory tract disease 
The term “respiratory tract infection” refers to infections of the upper or lower 
respiratory tract by bacteria, fungi or viruses. Symptoms associated with upper respiratory 
infection include the common cold, sore throat and tonsillitis while lower respiratory 
infections mainly induce bronchitis and pneumonia. Influenza, or shortly ‘flu’, can affect 
both parts of respiratory tract (Clark and Lynch, 2011; Govaert et al., 1998). According to the 
US Centers for Disease Control and Prevention (www.cdc.gov, 2015), influenza or influenza-
like illness is defined by a temperature higher than 37.8°C and either cough or sore throat in 
the absence of a known cause other than influenza virus (Harper et al., 2004). The WHO 
states that influenza is characterized by a sudden onset of high fever together with other 
symptoms, which differ between adults and children (www.who.int, 2015). High temperature, 
dry cough, sore throat and nasal congestion or runny nose, are common in both adults and 
children suffering from influenza. In contrast, headache and myalgia are more common in 
adults while vomiting and diarrhea are mainly observed in children (Clark and Lynch, 2011; 
Khandaker et al., 2011; Punpanich and Chotpitayasunondh, 2012; Tregoning and Schwarze, 
2010). Most patients recover from influenza symptoms within a week, but influenza can be 
associated with severe respiratory, cardiovascular and others complications, like acute 
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bronchitis, secondary bacterial pneumonia and otitis media (i.e. inflammatory diseases of 
middle ear) (Clark and Lynch, 2011; Harper et al., 2004; Punpanich and Chotpitayasunondh, 
2012). The following groups are at high risk for complications: adults aged 65 years or older, 
children younger than 2 years, pregnant women, individuals with chronic pulmonary or 
cardiovascular or hematologic or metabolic disorders, and persons with immunosuppression 
caused by either diseases, for instance HIV/AIDS, or medication (Clark and Lynch, 2011; 
Harper et al., 2004). 
2.2 Influenza virus 
 Influenza virus, the causative agent of influenza was first described in 1933 by Smith 
and colleagues. They showed that a filterable agent isolated from an individual with influenza 
symptoms caused an influenza-like illness in experimentally inoculated ferrets (Smith et al., 
1933). Subsequently, it was shown that influenza viruses can be propagated in embryonated 
chicken eggs, contain enzymes, i.e. neuraminidase, and recombine their genomes at high 
frequency. 
  2.2.1 Classification 
 In a phylogenetic-based taxonomy, influenza viruses belong to the category ‘RNA 
viruses’, subcategory ‘negative-sense single-stranded RNA viruses’, order 
‘Mononegavirales’, family ‘Orthomyxoviridae’. There are three genera of influenza viruses: 
influenza A virus (FLUAV), influenza B virus (FLUBV) and influenza C virus (FLUCV). 
The FLUAV can be additionally divided into subtypes on the basis of antigenic properties of 
two viral surface glycoproteins: hemagglutinin (HA, subtypes H1-H18) and neuraminidase 
(NA, subtypes N1-N11). Examples for influenza virus subtypes are FLUAV H1N1 (for 
instance the virus responsible for the ‘swine flu’ pandemic in 2009), FLUAV H3N2, FLUAV 
H5N1 (the viruses responsible for ‘avian flu’), FLUAV H17N10 and H18N11 (subtypes 
recently identified in bats). Further characterization of influenza virus strains includes 
information on the geographic origin, strain number, year of isolation and virus subtype, i.e. 
influenza virus A/Puerto Rico/8/34 (H1N1) is the 8
th
 strain of H1N1 subtype, isolated in 
Puerto Rico in 1934. 
 Influenza A virus 
FLUAV can infect people, birds, pigs, horses, whales, seals and other mammals. It is 
believed that water fowl is the natural reservoir of FLUAV (Horimoto and Kawaoka, 2005; 
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Palese, 2004; Schrauwen et al., 2014; Webster et al., 1995). However, FLUAV were recently 
detected in Guatemala yellow-shouldered bats and the role of bats in the influenza zoonosis is 
currently under intensive investigation (Tong et al., 2012; Tong et al., 2013). On the basis of 
molecular genetics and pathogenesis criteria, low pathogenic avian influenza viruses 
(LPAIV) and highly pathogenic avian influenza viruses (HPAIV) can be discriminated. Most 
of the known avian influenza viruses are LPAIV and induce no symptoms or mild disease in 
birds. In contrast, HPAIV cause severe disease with high mortality in poultry (Kuiken, 2013; 
Sonnberg et al., 2013; Spackman, 2014). LPAI viruses may evolve into HPAIV and cause 
disease outbreaks in poultry (Sonnberg et al., 2013). Humans can be infected with both with 
LPAIV and HPAIV. However, infection requires direct contact with infected sick or dead 
birds. Avian FLUAV of the following HA subtypes are known to infect both birds and 
people: H5, H7 and H9 (El Zowalaty et al., 2013; Herfst et al., 2014). Infection with HPAIV 
of the H5N1 subtype causes severe and frequently fatal disease and H5N1 viruses are 
currently circulating in Asia and Europe (El Zowalaty et al., 2013). Mild to severe, as well as 
fatal illness in humans have been observed upon infection with H7N7 (HPAIV) or H7N9 
(LPAIV) viruses (Puzelli et al., 2014; Shi et al., 2013). On the other hand, only 13 cases of 
infection with H9N7 avian FLUAV were reported, mainly recorded in Southern China and 
Hong Kong, and all patients fully recovered (Huang et al., 2015). 
 Influenza B virus 
FLUBV is known to infect humans and seals. Due to this limited host range, it is believed 
that FLUBV can cause epidemics but not pandemics. Moreover, influenza caused by FLUBV 
is frequently less severe in comparison to influenza upon FLUAV infection (Clark and 
Lynch, 2011; Paul Glezen et al., 2013). The virion structure and replication cycle of FLUBV 
is similar to that of FLUAV. In contrast to FLUAV, FLUB viruses are a mainly homogenous 
group, which started to diverge into two antigenically distinct lineages (Victoria and 
Yamagata lineages) in the 1970s (Biere et al., 2010). The reduced diversity of FLUBV 
compared to FLUAV reflects slower evolution (Nobusawa and Sato, 2006).   
 Influenza C virus 
Infections with FLUCV are much less frequent compared to FLUAV and FLUCV. They only 
cause mild illness, mainly in children (Clark and Lynch, 2011), and the viruses do not have 
pandemic potential. In contrast to FLUAV (genome and replication strategy are described in 
detail below) and FLUBV, FLUCV contain only 7 RNA segments, which encode 9 proteins 
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(Muraki and Hongo, 2010). Moreover, instead of HA and NA present in FLUAV and 
FLUBV (which are described in the chapter 3.3 and 3.5), FLUCV harbor a single surface 
glycoprotein, hemagglutinin-esterase, which mediates virus-cell fusion and plays a role in 
virus release (Herrler and Klenk, 1991). 
  2.2.2 Epidemiology 
 New epidemic FLUAV strains can emerge every 1 to 2 years and infection with these 
viruses is believed to be responsible for 3-5 million cases of severe illness every year (Palese, 
2004). The reason for the constant emergence of new FLUAV is the continuous acquisition 
of point mutations in NA and particularly HA (the function of these proteins is described in 
detail in the next paragraphs) (Horimoto and Kawaoka, 2005), a process termed antigenic 
drift. These mutations allow FLUAV to evade the humoral immune response and to 
constantly circulate in population with preexisting immunity (Medina and García-Sastre, 
2011). A hallmark of influenza viruses is their segmented RNA genome, as described below. 
The exchange of entire genomic segments (reassortment) between different FLUAV can 
allow the emergence of antigenically novel viruses, termed antigenic shift, against which the 
population is immunologically naïve (Horimoto and Kawaoka, 2005). A new influenza 
pandemic might be the consequence. In contrast to the annual epidemics, pandemics occur 
every 10 to 50 years (Potter, 2001). However, their consequences might be much more severe 
than influenza epidemics, as discussed below. 
Influenza epidemics (Seasonal flu) 
Each year, approximately 10% of the world’s population is infected with influenza 
viruses, and influenza-related complications cause 250.000-500.000 deaths. Moreover, 
influenza cases are associated with 87.1 billion USD of direct costs in the USA alone 
(Molinari et al., 2007). In the northern hemisphere, influenza waves are observed in fall and 
winter and are caused by the currently circulating FLUAV and FLUBV. In 2014-2015, in the 
USA the influenza season started at the 44
th
 week of 2014 and lasted until the 15
th
 week of 
2015 (Figure 1). The majority of cases were due to infection with FLUAV of the H1N1 or 
H3N2 subtype, and towards the end of the season the number of patients with FLUBV 
infection increased (Figure 1). Collectively, seasonal flu follows predictable seasonal 
patterns, occurs annually and usually causes big impact on society due to the pre-existing 
immunity, built up from previous exposure with similar strains of flu. 
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Figure 1. Influenza  surveillance. Depicted are numbers of positive specimens tested for the 
indicated influenza type (e.g. influenza virus B) and subtype (e.g. influenza virus A H3) as well as the 
percentage of positives among specimens analyzed during the influenza season 2014-2015 in the USA 
(FluView. A weekly Influenza Surveillance Report, www.cdc.gov). 
Influenza pandemics 
Spanish flu  
The Spanish influenza occurred in 1918-1919 and is described as one of three most 
destructive human pandemics, jointly with the plague of Justinian and the Black Death, 
during which deaths in hospitals may have exceeded 25% per night (Potter, 2001). The 1918 
influenza pandemic was caused by an H1N1 virus of unknown origin, although, some data 
suggest that the virus evolved from an avian virus with or without adaptation to an 
intermediate host (Schrauwen et al., 2014). In less than one year, the virus infected 50% of 
the world’s population and killed 40-50 million people worldwide (Palese, 2004). Unlike any 
other recorded influenza pandemic, the Spanish influenza mainly affected patients aged 20-
40, and the reasons for this are still unclear. One explanation might be lack of previous 
exposure to H1N1 viruses, since a H3 virus caused a pandemic in 1898-1900 as well as 
subsequent epidemics (Schrauwen et al., 2014). In contrast, older people might have 
previously been exposed to a H1 virus which caused a pandemic in 1830-1833 and 
subsequently circulated as a seasonal strain (Potter, 2001). As a consequence, the death rate 
decreased in people older than 40, only to rise again in the elderly, as is typical for influenza.  
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Asian flu 
The 1957 the ‘Asian flu’ was caused by an H2N2 virus, which contained HA, NA and 
polymerase basic 1 (PB1) genomic segments from an avian H2N2 virus and the remaining 
segments from the H1N1 virus circulating at this time (a descendant of the 1918 H1N1 virus). 
The pandemic claimed 1-2 million lives, and a fatal outcome was predominantly observed in 
children and the elderly, much in contrast to the 1918 pandemic (Potter, 2001). Most deaths 
were due to the secondary bacterial pneumonia, as commonly observed for influenza. 
Hong Kong flu 
In 1968, a reassortant H3N2 virus emerged with the HA and PB1 genomic segments 
from an avian influenza virus and the remaining segments from the previously circulating 
H2N2 virus. Due to the prior immunity in the human population against N2 neuraminidase, 
the pandemic was characterized by lower morbidity and mortality as compared to the 1957 
pandemic (Potter, 2001), although it was estimated that almost 1 million people died because 
of influenza and secondary bacterial pneumonia. 
Russian flu 
The fourth influenza pandemic of the 20st century unfolded in 1977 and was again 
caused by an H1N1 influenza virus. The virus caused disease mostly in younger people, born 
after 1950, due to pre-existing immunity in the older population, resulting from previous 
exposure to H1N1 FLUAV. The Russian H1N1 FLUAV strain was closely related to viruses 
circulating before 1950 (Potter, 2001), and its origins are unclear. The virus might have been 
accidentally released from a laboratory freezer or might have been introduced into the 
population in the course of vaccine trials with military recruits conducted in East Russia 
(Palese, 2004; Potter, 2001). 
Swine flu 
The first influenza pandemic of the 21st century started in spring 2009 in Mexico and 
within a few months the new virus, again of the H1N1 subtype, spread globally, resulting in 
100.000 to 300.000 deaths (York and Donis, 2013). The virus caused disease in  
a disproportionately high frequency among young adults, while people over 65 years old 
might have been partially protected, since the virus was relatively close to the H1N1 virus 
circulating before 1957 (Schultz-Cherry et al., 2013). In opposite to the 1918 FLUAV 
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responsible for the Spanish flu, the 2009 H1N1 FLUAV was a reassortant with NA and  
M genes from the ‘Eurasian’ swine influenza virus lineage while the rest of the genes 
originated from a triple reassortant virus, which contained genes of human, avian and swine 
origin (Schultz-Cherry et al., 2013; York and Donis, 2013). 
  2.2.3 Current approaches to prevent and treat influenza 
Influenza is frequently treated with supportive therapy, which includes bed rest, 
adequate hydration and administration of anti-fever drugs and painkillers, i.e. acetylsalicylic 
acid or ibuprofen. Additionally, nasal sprays, water vaporization and cough suppressants can 
be included. Antibiotic treatment should be applied only when secondary bacterial 
pneumonia is diagnosed (Harper et al., 2004). Specific anti-influenza therapy is available. 
However, it should be reserved for high risk patients or individuals with more severe disease 
course (Harper et al., 2004). Currently, there are two groups of antiviral drugs against flu: the 
M2 ion channel blockers (amantadine and rimantadine) and NA inhibitors (oseltamivir and 
zanamivir).  
Amantadine as well as rimantadine (an amine derivate of adamantine) block the viral 
M2 ion channel protein and thereby prevent from release of viral genetic material to the 
cytoplasm and thus suppress the viral replication (the viral structure and replication are 
described in the next paragraphs) (Fleming, 2001; Gu et al., 2013; Krol et al., 2014; Saladino 
et al., 2010). However, viruses rapidly acquires resistance mutations and up to 92% of the 
currently circulating H3N2 strains are amantadine/rimantadine resistant (Zhang et al., 2013), 
and the pandemic 2009 swine flu strain was found to be completely resistant to adamantine 
derivatives (Baranovich et al., 2015). Therefore, the WHO does not recommend the use of 
M2 ion channel blockers as anti-influenza drugs. 
The second class of anti-influenza drugs are NA inhibitors (oseltamivir and 
zanamivir), which inhibit release of progeny virions from infected cells. These compounds 
block the catalytic center of NA and thereby prevent FLUAV transmission from infected 
cells to neighboring cells (Krol et al., 2014; Shtyrya et al., 2009). The administration of these 
drugs during the first two days of influenza onset can significantly reduce illness duration and 
severity (Kidd, 2014; Saladino et al., 2010). The catalytic center of NA is highly conserved 
between different influenza strains and one would expect mutations in this domain to alter 
viral fitness (Shtyrya et al., 2009). Nevertheless, FLUAV strains resistant to oseltamivir 
emerged (for instance the 2009 pandemic FLUAV strain was resistant to oseltamivir) and 
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were efficiently transmitted, due to the presence of compensatory mutations, which allowed 
robust viral spread despite oseltamivir resistance (Baek et al., 2015; Baranovich et al., 2015; 
Duan et al., 2014; Kiso et al., 2010). In contrast, zanamivir resistance has been rarely 
reported to date (Thorlund et al., 2011). 
The most efficient strategy to fight infectious diseases is vaccination. Vaccination can 
prevent or at least ameliorate morbidity and mortality of diseases like chicken pox, polio, 
measles and tetanus. In the case of small pox, vaccination even allowed the eradication of the 
causative agent. Vaccination against influenza is available since the 1930s (Shope, 1936). 
However, due to constant antigenic drift of circulating viruses vaccination needs to be 
repeated annually.  At present, two types of influenza vaccines are available: trivalent and 
quadrivalent vaccines, which can contain either inactivated (whole inactivated viruses, split 
viruses, viral subunits) or live attenuated (less virulent) viruses (Soema et al., 2015). The 
trivalent influenza vaccines consist of two FLUAV strains and one FLUBV strain, while the 
quadrivalent vaccines contain combinations of two FLUAV and two FLUBV strains (Soema 
et al., 2015). In both cases, the vaccines are designed to stimulate the immune system to 
develop an adaptive response against viruses predicated to be circulating during the next 
influenza season. 
 2.3 Influenza A virus structure  
Influenza virus particles are enveloped and of spherical or filamentous form. The envelope 
contains that surface proteins HA and NA, which are detectable as glycoprotein ‘spikes’ upon 
electron-microscopic analysis, and the ion channel M2 (Fig. 2A) (Das et al., 2010). The 
envelope encloses the virion interior which contains eight segments (seven in the case of 
FLUCV) of the negative-sense single-stranded RNA genome. The genomic segments encode 
three subunits of the viral RNA-dependent RNA polymerase (polymerase acidic protein, PA; 
polymerase basic protein 1, PB1 and polymerase basic protein 2, PB2), the viral surface 
glycoproteins HA and NA, the ion channel M2, the nucleoprotein (NP), matrix proteins  
(M1 and M2 ion channel) and two non-structural proteins (NS1 and NS2). The second 
FLUAV RNA genomic segment, except of PB1, encodes two additional protein: PB1F2 and 
N40, which play role in promoting virus replication and increase pathogenesis (Chakrabarti 
and Pasricha, 2013). The viral RNA is associated with the viral RNA polymerase (PB1, PB2 
and PA) and is coated with multiple nucleoproteins (NPs) to form the so called viral 
ribonucleoprotein (vRNP) complex. The vRNPs are surrounded by a layer of the matrix 
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protein, M1, which is located underneath the viral envelope. The lipid layer originated from 
the host cell during and was acquired during budding of progeny particles from infected cells 
(Fig. 2B). 
 
Figure 2. Influenza A virus particle. A) A Zernike phase contrast electron micrograph of ice-
embedded FLUAV.  Spherical and elongated virions in which the envelope (between red arrowheads), 
ribonucleoproteins complexes (yellow arrows) and surface glycoproteins (blue arrowheads) are 
indicated (Figure was modified from Yamaguchi et al., 2008). B) Scheme of FLUAV virions. The 
virus particle contain eight ribonucleoprotein complexes (vRNPs), which harbor negative sense single 
stranded RNA segments, associated with the nucleoprotein (NP) and three polymerase proteins (PA, 
PB1, PB2). The vRNPs are connected via the matrix protein (M1) with the viral envelope, which is 
spiked with surface glycoproteins: hemagglutinin (HA), neuraminidase (NA). In addition, the M2-ion 
channel protein is inserted into the envelope (Figure was taken from Harimoto and Kawaoka, 2005). 
2.4 Viral life cycle 
The viral life cycle commences with attachment of virions to target cells (Luo, 2012). 
This process is mediated by the HA protein, which binds to α-2,3- (avian viruses) or α-2,6-
linked (human viruses) sialic acids on cellular glycoproteins or glycolipids  (Step 1, Figure 1) 
(Matrosovich et al., 2009). Subsequently, virus is transported to the cell interior by 
endocytosis (Step 2, Figure 3) (Luo, 2012). Next, the acidification of endosomes triggers 
conformational changes in HA, which bring about fusion of the viral and the endosomal 
membrane (Step 3, Figure 3) (Sriwilaijaroen and Suzuki, 2012). Moreover, proton transport 
into the virion interior via the ion channel M2 abrogates the interaction between vRNPs and 
the M1 matrix protein and the release if vRNPs into the host cell cytoplasm (Step 4, Figure 3) 
(Sun, 2013). After transport to the nucleus, synthesis of viral mRNAs starts (Step 5, Figure 3) 
A) B) 
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followed by protein expression (Step 6, Figure 3) (Das et al., 2010). The nascent polypeptides 
of the viral surface proteins HA and NA are imported and N-glycosylated in the endoplasmic 
reticulum. The N-glycans are trimmed in the Golgi apparatus and the mature proteins are 
transported to the cell surface, where the HA of human influenza viruses can be 
proteolytically processed by type II transmembrane serine proteases (Step 7, Figure 3) (Das et 
al., 2010). In the nucleus, newly formed viral RNAs associate with NP and viral polymerase 
subunits to form vRNPs, which can be exported from the nucleus as a function of nuclear 
export protein (NEP, also referred to as non-structural protein 2, or NS2) (Step 8, Figure 3) 
(Das et al., 2010). At the cellular surface, the vRNPS are incorporated into budding viruses 
via interactions between M1 and the cytoplasmic tails of the viral surface proteins (Step 9, 
Figure 3) (Ali et al., 2000). Finally, progeny particles are released from the cells and this 
process is promoted by NA-mediated cleavage of sialic acid residues on cellular and viral 
factors present at the cell surface (Step 10, Figure 3) (Rossman and Lamb, 2011). 
 
Figure 3. Influenza virus life cycle. (Figure was taken from Zmora and Pöhlmann, 2015) 
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2.5 Hemagglutinin 
  2.5.1 Structure and function 
HA is inserted in the viral envelope, coded by the 4
th
 RNA segment and comprises 
approximately 560 amino acid residues with a molecular weight of approximately 60 kDa 
(for unglycosylated HA) (Das et al., 2010; Schrauwen et al., 2014; Sriwilaijaroen and Suzuki, 
2012). The molecular weight increases upon N-glycosylation and the increase depends on the 
number and complexity of N-glycans attached to HA (Sriwilaijaroen and Suzuki, 2012). An 
N-terminal signal sequence mediates import of the nascent HA0 polypeptide chain into the 
ER, where the signal sequence is removed, the protein is folded and modified by high-
mannose N-glycans (Sriwilaijaroen and Suzuki, 2012). In addition, HA homotrimers are 
formed in the ER. In the Golgi apparatus, the N-glycans are trimmed and HA of HPAIV is 
proteolytically cleaved into the surface unit, HA1, and the transmembrane unit, HA2 (Bertram 
et al., 2010b; Bottcher-Friebertshauser et al., 2013). In contrast, cleavage of HA of LPAIV 
and human influenza viruses is believed to occur during or after transport of the protein to the 
cell surface (Bertram et al., 2010b), as discussed below. HA is the major target for the 
neutralizing antibody response and the decoration of HA with N-glycans is believed to mask 
underlying epitopes from recognition by antibodies (Das et al., 2010). The number of signals 
for N-glycosylation varies between FLUAV isolates: The HA of the pandemic 1918 FLUAV 
contains only one N-glycosylation site in the globular head domain at N95, while the 
seasonal H1N1 FLUAV A/Puerto Rico/8/34  has four N-glycosylation sites: at position N95, 
N129 or N131, N158 and/or N163 or N165 in the same region (Igarashi et al., 2010).  
A different seasonal FLUAV strain, A/Texas/36/91, contains five glycans on the HA head: at 
positions N71, N104, N142, N177 and N286, while the more recent strain A/Solomon 
Island/2006 possesses four glycans at positions N71, N104, N142 and N177 and shows the 
evolutionary trend to lose the N-glycosylation site at position N286  (Sun et al., 2013). 
The HA is a type I transmembrane protein, i.e. the N-terminal part is located outside 
the cell while a C-terminal hydrophobic transmembrane domain anchors HA in the plasma 
membrane and the viral envelope, respectively (Harrison, 2015; Sriwilaijaroen and Suzuki, 
2012; White et al., 2008). The HA cytoplasmic tail, which consists of 10-11 amino acids, is 
not required for intracellular transport to the plasma membrane (Jin et al., 1994), but it was 
shown that the lack of the cytoplasmic tail resulted in defective virion morphogenesis and 
improper genome packaging (Zhang et al., 2000). Additionally, it was also demonstrated that 
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palmitoylation of the HA cytoplasmic tail is dispensable for HA-mediated membrane fusion 
in the case of H3 subtype HA (Chen et al., 2005). HA has a cylindrical shape (135 A long and 
35-70 A wide) and forms ‘spikes’ on the virion surface, which can be readily visualized via 
electron microscopy (Fig. 2B) (Yamaguchi et al., 2008). Two major domains have been 
identified in HA: The globular head domain, which is mainly build up from the HA1 subunit, 
and a stalk-like domain, called stem, which contains parts of HA1 and the entire extracellular 
part of HA2 (Figure 4) (Chen et al., 1998; White et al., 2008). The globular head contains 
HA1 residues 116-261, which are folded into a jelly-roll motif of eight stranded antiparallel β-
sheets, and harbor sialic acid binding sites at the distal tip, as well as major antigenic regions 
(Figure 4) (Chen et al., 1998). In contrast, the HA stem contains an elongated central coiled-
coil, formed by the non-covalent association of three helices of each monomer (Chen et al., 
1998). The surface loop structure at the HA stem domain contains a cleavage site (Figure 4) 
for host cell proteases and cleavage is required for HA-driven fusion of viral and cellular 
membranes and thus for viral infectivity (Chen et al., 1998). The proteolytic cleavage induces 
the repositioning of the highly conserved N-terminus of the HA2 subunit, which encodes the 
fusion peptide, to the interior of the HA trimer (Chen et al., 1998). The HA fusion peptide is 
well conserved among all HAs subtypes, and similarly to other viral fusion peptides, contains 
GxxG or GxxxG motifs, which are believed to be responsible for the interactions with 
membranes or transmembrane domains (Cross et al., 2009; Worch, 2014). Among the fusion 
peptide amino acid sequence, many hydrophobic amino acids can be found, with acidic 
residues at the conserved positions 11, 15 and 19, which may contribute to the insertion of the 
fusion peptide into the target cell membrane (Cross et al., 2009; Worch, 2014), as describe 
below.  
The FLUAV HA has two key functions: i) to bind to the major viral receptor 
determinant, sialic acid attached to proteins or lipids on the cell membrane, and ii) to fuse the 
viral membrane with a target cell membrane. The HA proteins of influenza viruses exhibit 
differential receptor specificity: Human and swine influenza viruses bind to α-2,6-linked 
sialic acid, while avian and equine influenza viruses prefer sialic acid attached to galactose by 
α-2,3-linkeage (de Graaf and Fouchier, 2014; Matrosovich et al., 1993; Suzuki et al., 2000). 
The receptor preference correlates with the availability of appropriately linked sialic acids on 
cells of the respiratory tract: The majority of sialic acid isomers in the upper respiratory tract 
of humans is attached to the galactose by α-2,6-linkage, while in the lower respiratory tract 
the α-2,3-sialic acid isomers are predominant (Matrosovich et al., 2009; Suzuki et al., 2000). 
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In case of swine, α-2,6-linked sialic acids are the predominant form in both upper and lower 
respiratory tract, while α-2,3-linked sialic acids are found in small amounts in bronchioles 
and alveoli (Trebbien et al., 2011). The avian respiratory tract contains both α-2,3- and α-2,6-
linked sialic acid (Trebbien et al., 2011) However, in the intestinal tract, a target of FLUAV 
infection in birds but not mammals, α-2,3-linked sialic acids predominate (Kumlin et al., 
2008). The binding site for α-2,6-linked sialic acid in HA of the H1 subtype is localized on 
the distal tip of HA1 subunit (Fig. 4, marked with star) and is formed by three secondary 
structures: one helix (190-helix, residues 190-198) and two loops (130-loop, residues 135-
138; and 220-loop, residues 221-228) (Chen et al., 1998; Sriwilaijaroen and Suzuki, 2012) 
(Mair et al., 2014; Wilks et al., 2012). 
The second major HA function, mediation of viral entry, is described in the two 
following paragraphs. 
Figure 4. The structure of influenza A virus hemagglutinin. Structure of trimers of H1 subtype 
precursor HA0 in the side face-centered (A) or back C3 axis (B) orientation, with carbohydrates 
shown in red.  The receptor binding site (star) and the cleavage site (arrowhead) are indicated. The 
figure was generated using Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). 
  2.5.2 Class I fusion proteins and membrane fusion mechanism 
 The influenza virus HA exhibits a structural and functional organization also found in 
other viral glycoproteins, for instance those of paramyxoviruses, retroviruses, filoviruses, and 
coronaviruses, which are collectively termed class I membrane fusion proteins (Kielian, 
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2014; White et al., 2008). Class I membrane fusion proteins are synthesized as single-chain 
precursors and assemble into trimers in the pre-fusion and post-fusion state. Upon successful 
execution of membrane fusion they form a characteristic six-helix-bundle structure (also 
called trimer of hairpins), consisting of a central N-terminal trimeric α-helical coiled-coil 
decorated by three C-terminal helices (Colman and Lawrence, 2003; Harrison, 2015; White et 
al., 2008). The single-chain precursor needs to be proteolytically processed to gain its 
fusogenic activity. This process occurs late in the biosynthetic pathway, as the fusion 
proteins, once cleaved, are in a metastable state and rapidly transit into an inactive, highly 
stable conformation (Colman and Lawrence, 2003; Harrison, 2015). In contrast to class II 
membrane fusion proteins, influenza HA and other viral class I membrane fusion proteins are 
characterized by a perpendicular orientation with respect to the viral membrane. Moreover, 
the predominating structural element in class I membrane fusion proteins are α-helixes, while 
β-sheets are characteristic for class II membrane fusion proteins and both α-helixes and β-
sheets are found in class III membrane fusion proteins (White et al., 2008). In contrast, all 
classes of membrane fusion proteins transit into the six-helix-bundle structure after successful 
completion of membrane fusion (Colman and Lawrence, 2003; Harrison, 2015; Kielian, 
2014; White et al., 2008). 
 Host cell entry driven by HA commences with binding of HA to appropriately linked 
sialic acids, followed by endocytic uptake of virions, as described in paragraph 3.4. At this 
stage, the fusion peptide of HA is hidden within the molecule (Figure 5). As endosomes 
become acidified, low pH triggers a series of conformational changes in HA. First, the HA1 
subunit dissociates from the HA2 subunit although both remain linked by a disulfide bond 
(Harrison, 2015; Kielian, 2014). The dissociation of HA1 allows the N-terminal fusion 
peptide in HA2 to leave its buried position and to transit to the tip of the HA2 trimer (Cross et 
al., 2009; Harrison, 2015; Worch, 2014). The loop between the shorter and longer helices in 
HA2 becomes a helix (so called loop-to-helix transition), which creates a long, three-chain 
coiled coil. In the course of these transitions the fusion peptide is projected towards and 
ultimately inserts into the target membrane (Figure 5) (Cross et al., 2009; Worch, 2014). 
Next, the amino acids at HA2 positions 106-112 undergo a helix-to-loop transition, which 
causes the collapse of the extended intermediate and generates the post-fusion conformation, 
in which the fusion peptides are located in close proximity to the transmembrane domains. As 
a consequence of these transitions, target and viral membranes are pulled together and fuse 
(Figure 5) (Harrison, 2015). Membrane fusion commences with a hemifusion intermediate 
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(Worch, 2014), a condition in which the outer leaflets of two bilayers are combined and the 
inner leaflets remain intact, followed by formation of a fusion pore (Figure 5). 
Figure 5. Scheme of membrane fusion driven by class I membrane fusion proteins.  (1) The 
fusion peptide (green arrowhead), located in the transmembrane subunit, is hidden within the 
molecule. (2) A trigger, frequently low pH, induces conformational changes in the fusion protein, in 
the course of which an extended intermediate is formed and the fusion peptide is inserted into the 
target cell membrane. At this stage, the fusion protein is connected to the viral (purple) and cellular 
(blue) membranes. (3) Fusion peptide insertion into the target cell membrane and conformational 
changes in the fusion protein alter the viral and the target cell membrane curvature and pull them into 
close contact. (4) Subsequently, the transmembrane unit refolds into a trimer-of-hairpins structure, 
resulting in the formation of a hemifusion intermediate, in which viral and host cell membranes are 
mixed. (5) The completion of the conformational changes allows the opening of the fusion pore and 
thus the finalization of the membrane fusion reaction (Figure was modified from Kielian, 2014). 
2.5.3 Proteolytic cleavage as a requirement of membrane fusion 
The HA-driven fusion of the viral and the endosomal membrane allows the release of 
the viral genetic material into the host cell cytoplasm and is essential for viral replication. HA 
is synthesized as an inactivate precursor and gains its membrane fusion activity only upon 
cleavage by a host cell protease (Lazarowitz et al., 1973a), which liberates the fusion peptide 
from the HA1 subunit, as discussed above. The HA0 precursor is cleaved at a linker sequence 
in a loop located between the HA1 and HA2 subunits (Fig. 6). First, HA is cleaved by 
endoproteases at the carboxyl terminus of an arginine located at the loop linking the HA1 and 
HA2 subunits and as a result the N-terminus of HA2 is generated. Subsequently, the  
C-terminal arginine of the HA1 subunit is removed by an unknown cellular carboxypeptidase 
(Garten and Klenk, 1983). Whether this step is critical for HA function remains unclear 
(Hamilton et al., 2012b). The major structural consequence of proteolytic cleavage is the 
generation of a new C-terminus of HA1 subunit and a new N-terminus of the HA2 subunit as 
well as the relocation of N-terminal fusion peptide (Cross et al., 2009). 
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FLUAV can contain different amino acid sequence at the cleavage site. The HA0 with 
series of basic (multibasic) amino acids R-X-R/K-R↓G-L-F or R-X-X-R↓G-L-F, where X is 
a non-basic amino acid at the proteolytic cleavage site and ↓ indicates cleavage site, is found 
mainly in HPAIV, i.e. H5 and H7 avian influenza viruses (Garten et al., 2015; Hamilton et 
al., 2012b; Stieneke-Grober et al., 1992). In contrast, LPAIV as well as human influenza 
viruses contain P3-P3’ sequence motif Q/E-S/T-R↓G-L-F, with a single arginine at the 
cleavage site, a so called mono-basic cleavage site (Garten et al., 2015). Depending on the 
sequence of the cleavage site, different proteases are involved in the proteolytic cleavage and 
this has important consequences for spread and pathogenesis of avian influenza viruses 
(Hamilton et al., 2012b). The poly-basic cleavage site of HPAIV is processed intracellularly 
in the trans-Golgi compartment by ubiquitously expressed proteases, furin and other 
proprotein convertases (Stieneke-Grober et al., 1992). Due to the expression of these 
proteases in a wide range of cells and tissues, HPAIV can spread systemically and frequently 
cause fatal disease. In contrast, it is thought that expression of proteases activating LPAIV 
HA is restricted to the aerodigestive tract of these animals (Bertram et al., 2010b). As  
a consequence, viral spread is limited to these organs and can thus be controlled by the 
immune system. In addition, recent studies suggested that there are also factors, other than 
cleavage site, which play a role in HA activation. Kido et al. showed that the flanking regions 
of cleavage site play a role in HA cleavage by host cell proteases and Hamilton et al. 
suggested that the HA cleavage can be controlled by many other factors, since for most of the 
HA, the cleavage site amino acid sequence is identical (Hamilton et al., 2012b; Kido et al., 
2012). 
The HAs of human influenza viruses, including that of the highly pathogenic 1918 
influenza virus, is monobasic and the nature of the host cell proteases responsible for 
activation of these HA proteins (as well as the HA proteins of LPAIV) is unclear. Several 
studies proposed that secreted protease expressed in the aerodigestive tract, including 
plasmin, tryptase Clara are responsible (Gotoh et al., 1990; Kido et al., 1992; Lazarowitz et 
al., 1973b; Murakami et al., 2001). However, many of these studies were conducted with 
recombinant proteins and the concentrations tested might not reflect those present in the 
relevant tissues of the infected host. Additionally, in case of the laboratory adapted FLUAV 
A/WSN/33, the NA was shown to sequester plasminogen, which upon conversion to plasmin, 
facilitates HA cleavage (Goto and Kawaoka, 1998). Similarly, the NA of the 1918 influenza 
virus can facilitate trypsin-independent activation of HA (Tumpey et al., 2005). However, 
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this process is cell line-specific and plasminogen-independent (Chaipan et al., 2009), and the 
mechanism remains unclear.  
A study by Zhirnov and colleagues showed that cleavage of influenza virus HA in 
human respiratory epithelium is a cell-associated process, accomplished by unknown serine 
proteases (Zhirnov et al., 2002). These results suggested that membrane-associated and not 
secreted proteases are responsible for activation of human influenza viruses and triggered 
efforts to identify the responsible enzymes. A study by Böttcher and colleagues showed that 
influenza viruses representing all subtypes pandemic in humans (H1N1, H2N2 and H3N2) 
are activated by TMPRSS2 and HAT (human airway trypsin-like protease), members of the 
type II transmembrane serine protease (TTSP) family, at least upon directed expression of 
these enzymes in a cell line (Böttcher et al., 2006). Subsequent studies showed confirmed 
activation of HA by TMPRSS2 and HAT, and showed that another TTSP, TMPRSS4, can 
also activate HA (Chaipan et al., 2009; Sawoo et al., 2014). These studies focused research 
interest on the role of TTSPs in viral infection, particularly on the question whether these 
enzymes can support viral spread in the infected host. 
Figure 6. Proteolytic cleavage of influenza hemagglutinin. The single chain precursor of 
hemagglutinin, HA0, is cleaved into two subunits HA1 (blue) and HA2 (red) by host cell proteases. 
The cleavage site is located in a loop between HA1 and HA2 (yellow). After cleavage, residues 323 in 
HA1 and 1-12 in HA2 relocate, while residues 1-322 in HA1 and 13-137 in HA2 occupy the same 
position before and after proteolytic processing. Proteolytic cleavage liberates the fusion peptide in 
HA2 from HA1 but both subunits remain covalently linked by a single disulfide bond (Figure was 
modified from Chen et al., 1998). 
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2.6 Type II transmembrane serine proteases 
  2.6.1 Structure and function 
 The type II transmembrane serine protease (TTSP) family is composed of more than 
20 members and constitutes the largest group of membrane-anchored serine proteases. These 
proteins are synthesized as single-chain inactive precursors, zymogens, and display the 
following domain organization: The N-terminus is located in the cytoplasm and is followed 
by a transmembrane domain, a stem domain and a catalytic serine protease domain (Fig. 7) 
(Antalis et al., 2011). The activation of TTSP zymogens requires cleavage after a basic amino 
acid residue (Arg or Lys) located in a conserved activation motif at the N-terminus of the 
catalytic domain (Bugge et al., 2009). After cleavage, the catalytic domain remains associated 
with the remainder of the molecule due to a disulfide bond. However, this bond can be 
severed, for instance by mechanical stress, resulting in the release of the enzymatically active 
protease domain in the extracellular space (Szabo and Bugge, 2011). Several TTSPs, 
including matriptase, hepsin, TMPRSS2, TMPRSS3 and TMPRSS4 can undergo 
autocatalytic activation in vitro (Antalis et al., 2011). However, the mechanism of 
autoactivation is still unclear and probably involves oligomerization or spontaneous 
conformation-driven hydrolysis (Antalis et al., 2011; Bugge et al., 2009). 
 The TTSP domains have distinct functions in TTSP biology: The cytoplasmic tail and 
transmembrane domain target the proteases to the plasma membrane and localize their 
activities to specific sites, i.e. HAT on the basolateral and apical surfaces of polarized cells 
(Garten et al., 2015). In contrast, the stem region, which can contain up to 11 different 
modules with sequence similarity to cellular proteins, appears to facilitate interactions with 
cellular binding partners and to contribute to enzymatic activity of TTSPs (Antalis et al., 
2011). Its presence is essential for the cleavage of certain physiological substrates (Bugge et 
al., 2009). Moreover, the stem region can contribute to the cellular localization, activation, 
inhibition, and/or substrate specificity of TTSPs (Antalis et al., 2011). The serine protease 
domain is responsible for the catalytic activity and contains a catalytic amino acid triad 
(histidine, aspartic acid and serine). It was shown that the catalytic domains of all TTSPs 
possess two adjacent, six-stranded β-barrel domains, connected via three linking trans-
domain segments (Bugge et al., 2009). The catalytic triad is located along the junction 
between two barrels and the active site cleft runs perpendicularly to this junction. Depending 
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on the size, shape and charge distribution within this pocket, different substrates are 
recognized and processed. 
The proteolytic processing of HA and other substrates by TTSPs depends on a two-
step mechanism: i) an acylation step, in which an intermediate between enzyme and 
polypeptide is formed and a fragment of the polypeptide is lost, and ii) a deacylation step, in 
which water launches a nucleophilic attack on the intermediate, resulting in the hydrolysis of 
polypeptide (Antalis et al., 2011).  
Four TTSP subfamilies have been defined according to phylogenetic analysis and 
similarities in domain structure: Hepsin/TMPRSS, Matriptase, Corin and HAT/DESC (Figure 
7). The biggest subfamily, Hepsin/TMPRSS, contains seven members (enteropeptidase, 
hepsin, TMPRSS2, TMPRSS3, TMPRSS4, TMPRSS5 and MSPL). Except for 
enteropeptidase, all members of the Hepsin/TMPRSS subfamily contain a group A scavenger 
receptor domain in their stem regions. These proteases are predominantly expressed in fetal 
liver and kidney, prostate, as well as in the lung and parts of the gastrointestinal tract (Antalis 
et al., 2011; Uhlen et al., 2015). The HAT/DESC subfamily comprises HAT, DESC1, 
TMPRSS11A, TMPRSS11B and TMPRSS11F and these enzymes contain a single SEA (sea 
urchin sperm protein/enteropeptidase/agrin) domain in the stem (Antalis et al., 2011). The 
expression of the HAT/DESC subfamily members is more restricted in comparison to 
members of the Hepsin/TTSP family, and is limited to the upper respiratory tract (bronchus, 
trachea and nasal gland) (Antalis et al., 2011; Uhlen et al., 2015). The Matriptase subfamily 
contains four members, three highly homologous proteases (matriptase, matriptase-2 and 
matriptase-3) and polyserase-1, which were found to be expressed in human breast cancer 
cell lines (matriptase)(Jin et al., 2005), liver (matriptase-2) (Uhlen et al., 2015), brain, ovary, 
testis and salivary gland (matriptase-3) (Szabo et al., 2005) as well as skeletal muscles, 
placenta and heart (polyserase-1) (Cal et al., 2003). The smallest TTSPs subfamily contains 
only one member, corin, which is mainly expressed in the heart (Chen et al., 2010). 
TTSPs may play a role in development and homeostasis. For instance, matriptase is 
essential for hair follicle development (List et al., 2006) and matriptase-2 contributes to iron 
metabolism (Wang et al., 2014). A major function of TTSPs is the activation of precursor 
molecules. For instance, corin converts pro-atrial natriuretic peptide to atrial natriuretic 
factor, a cardiac hormone responsible for blood pressure regulation and cardiac function 
(Knappe et al., 2004). TTSPs can process a range of substrates, including peptide hormones, 
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growth and differentiation factors, receptors, enzymes and adhesion molecules (Antalis et al., 
2011). Due to the important biological functions of many TTSPs, changing their 
expression/structures/activities can results in several pathological conditions. It was 
demonstrated that single nucleotide polymorphisms in the corin gene, which alter the amino 
acid sequence of the frizzled domain located in the corin stem region, affects zymogen 
activation and activation of atrial natriuretic factor and is associated with hypertensive 
disease in humans (Knappe et al., 2004). TMPRSS3 and TMPRSS5 are expressed in inner ear 
tissues and mutations in these genes have been found in patients with familiar congenital 
deafness (Guipponi et al., 2008a; Guipponi et al., 2002). There is also growing evidence for 
the participation of TTSPs in the pathogenesis of inflammatory and neoplastic diseases. It is 
well established that TMPRSS2 participates in prostate cancer development. Thus, tmprss2 
mRNA levels are increased in androgen-dependent prostate cancer (Lucas et al., 2008), and 
tmprss2 gene duplications were observed in cancer patients (Afar et al., 2001). Lucas et al. 
demonstrated also that the TMPRSS2 is expressed at high levels in primary and metastatic 
prostate cancers, and the TMPRSS2 cellular localization in most high-grade cancers was 
altered (Lucas et al., 2008). Additionally, it was demonstrated that the most frequent genomic 
alteration in prostate cancer is the fusion of TMPRSS2 with ERG (estrogen regulated gene) 
(Gasi Tandefelt et al., 2014). Due to the fact that TMPRSS2 is an androgen-responsive gene 
(Lucas et al., 2008), ERG overexpression as an effect of gene fusion can contribute to 
development of androgen-independence in prostate cancer by changes in the androgen 
receptor signaling (Hossain and Bostwick, 2013).  Similarly, it is believed that dysregulated 
expression of matriptase promotes cancer development by processing the pro-forms of 
urokinase-type plasminogen activator and hepatocyte growth factor (Benaud et al., 2002), 
which augment invasive cellular growth. However, the current understanding of the impact of 
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Figure 7. The type II transmembrane serine proteases. The enzymes are grouped according to 
similarities in domain structure and amino acid sequence homology. The first and last amino acid 
position in each domain is indicated above the domain. The HA-activating proteases are indicated in 
red, enzymes which fail to activate FLUAV are marked in green and enzymes not tested for HA 
activation are marked in black. Protease domain: serine protease domain; activation domain: pro-
domain; TM: transmembrane domain; GPI anchor: glycosyl-phosphatidylinositol linkage domain; 
LDLRA: LDL receptor class A domain; MAM: meprin, A5 antigen, and receptor protein phosphatase 
μ domain; CUB: Cls/Clr, urchin embryonic growth factor and bone morphogenetic protein-1; SEA: 
sea urchin sperm protein, enteropeptidase, agrin domain; Fz: frizzled domain; SR: Group A scavenger 
receptor domain (Figure was modified from Antalis et al., 2011). 
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  2.6.2 Role of TMPRSS2 in FLUAV activation 
The observation that TMPRSS2 can activate HA upon directed expression in cell 
culture raised the question whether this protease might contribute to viral spread in the 
infected host. A series of studies indicate that this is indeed the case: It was demonstrated that 
endogenous expression of TMPRSS2 is responsible for trypsin-independent spread of 
FLUAV in the human cell lines Calu-3 (Böttcher-Friebertshäuser et al., 2011) and Caco-2 
(Bertram et al., 2010a) and its was shown that TMPRSS2 is coexpressed with α-2,6-linked 
sialic acid in human respiratory epithelia (Bertram et al., 2012). Notably, cleavage of HA by 
TMPRSS2 and HAT might proceed in different cellular compartments: HAT cleaves FLUAV 
HA at the cell surface and might proteolytically process HA of incoming viruses (Böttcher-
Friebertshäuser et al., 2010), although this is debated (Bertram et al., 2010b), as well as 
newly synthesized viral glycoprotein, while TMPRSS2 cleaves only newly synthesized HA 
within the infected cell (Böttcher-Friebertshäuser et al., 2010). Finally, Hatesuer and 
colleagues demonstrated that TMPRSS2 is essential for influenza H1N1 virus spread and 
pathogenesis in mice (Hatesuer et al., 2013). This study showed that the tmprss2 knock-out 
mice were protected from viral spread and pathogenesis upon infection with H1N1 FLUAV, 
due to the lack of HA proteolytic processing (Hatesuer et al., 2013), a results that was 
confirmed by two subsequent studies (Sakai et al., 2014; Tarnow et al., 2014), which 
examined activation of H1N1, H3N2 and H7N9. In contrast, Hatesuer and colleagues 
demonstrated that tmprss2-deficient mice were not completely resistant to infection with 
H3N2 FLUAV (Hatesuer et al., 2013), suggesting that certain FLUAV might be able to 
hijack proteases other than TMPRSS2 for their spread in the host, and members of the TTSP 
family are attractive candidates. Indeed, several TTSPs other than TMPRSS2 can activate HA 
in cell culture but their potential role in FLUAV spread in the infected host is unknown. 
The finding that TMPRSS2 can activate influenza HA raised the question whether this 
protease and related TTSP can also activate the glycoproteins of other viruses. Indeed, 
TMPRSS2 was found to cleave and activate the surface glycoprotein of coronaviruses,  
i.e. severe acute respiratory syndrome (SARS) coronavirus (Bertram et al., 2011; Kawase et 
al., 2012; Matsuyama et al., 2010; Shulla et al., 2011), Middle East respiratory syndrome 
(MERS) coronavirus (Gierer et al., 2013; Shirato et al., 2013), 229E coronavirus (Bertram et 
al., 2013), porcine epidemic diarrhea virus (PEDV) (Shirato et al., 2011), human 
metapneumovirus (Shirogane et al., 2008), human parainfluenza virus (Abe et al., 2013) and 
hepatitis C virus (Esumi et al., 2015). In sum, TMPRSS2 is hijacked by several viruses to 
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promote their spread and inhibitors targeting this protease might thus exert broad antiviral 
activity. TMPRSS2 expression is dispensable for normal development and homeostasis in 
mice (Kim et al., 2006), suggesting that blockade of TMPRSS2 might not be associated with 
substantial unwanted side effects. 
2.6.3 Role of type II transmembrane serine proteases in influenza virus 
replication: Impact on steps other than HA activation 
 Recent findings suggest that TMPRSS2 might impact viral spread at stages other than 
HA activation. Release of PEDV from infected cells was shown to be augmented by 
expression of TMPRSS2 and this effect was not observed in the presence of leupeptin,  
a broad spectrum protease inhibitor active against TMPRSS2 (Shirato et al., 2011). In the 
absence of active TMPRSS2 infected cells retained large clusters of virions on their surface 
and these structures were detached from cells upon trypsin treatment (Shirato et al., 2011). 
Collectively, these findings suggest that TMPRSS2 and potentially other TTSPs might 
promote release of certain viruses from infected cells, likely due to inactivation of a cellular 
factor which negatively regulates release of progeny virions. The interferon-induced antiviral 
host cell factor tetherin (CD317, BST-2) is such a factor: tetherin restricts replication of many 
enveloped viruses by blocking their release from the infected cells (Neil et al., 2008; Van 
Damme et al., 2008). The key to the tetherin’s antiviral activity is its membrane topology: in 
opposite to TTSPs and HA, both N- and C- termini of tetherin are membrane anchored. This 
particular architecture allows the protein to insert one of its termini in the budding viral 
membrane, with the second one remaining in the host cell, thereby generating a physical 
bridge which results in virus trapping on the cell surface (Neil et al., 2008). Recently, it was 
also demonstrated that tetherin serves as a pattern recognition receptor, which induces  
NF-κB-dependent proinflammatory gene expression in virus infected cells (Galao et al., 
2012). Importantly, treatment of cells with trypsin abrogates tetherin’s antiviral activity 
(Hammonds et al., 2010) raising the question whether endogenously expressed serine 
protease, in particular TTSPs, can also counteract tetherin. 
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3. Aims 
The influenza virus hemagglutinin (HA) is inserted into the viral envelope and 
mediates viral entry into the host cell. HA is synthesized as a single-chain precursor and 
depends on proteolytic activation by cellular enzymes to gain its ability to fuse membranes, 
which is a prerequisite to infectious viral entry. TMPRSS2, which belongs to the type II 
transmembrane serine protease (TTSP) family, was found to be essential for spread of 
influenza viruses of the H1N1 subtype in infected mice. Thus, TMPRSS2 is a potential target 
for antiviral intervention. However, an H3N2 virus was less dependent on TMPRSS2 and 
might hijack other TTSPs for spread in the host. Indeed, several members of the type II 
transmembrane serine protease (TTSP) family, i.e. TMPRSS2, TMPRSS4, HAT and 
matriptase, can activate HA in cell culture and potentially in the host. However, many TTSPs 
have not been examined for their ability to activate HA and the impact of alternative splicing 
of TTSP transcripts on HA activation by the encoded proteins are unknown. Moreover, it is 
currently unclear why only some TTSPs can activate HA, while other, closely related 
proteases cannot. Finally, it remains to be elucidated whether TTSPs might promote influenza 
virus infection by mechanisms independent of HA activation. Such a possibility is suggested 
by the observation that TMPRSS2 facilitates release of an animal coronavirus from infected 
cells, potentially by inactivating an antiviral cellular factor. 
Therefore, four aims were defined for the present study: 
i) to screen the TTSP family for new activators of human influenza viruses, 
ii) to identify molecular determinants in TTSPs, which control the ability of these enzymes to 
cleave and activate HA, 
iii) to test whether alternative splicing of TMPRSS2 alters HA cleavage, 
iv) to test whether TMPRSS2 can promote influenza virus release, potentially by 
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Analysis of the expression of type II transmembrane serine proteases by western blot (Fig. 
1A) and flow cytometry (Fig. 1B). Analysis of the proteolytic cleavage of the coronavirus 
proteins  (Fig. 2A and 2B). Determination whether the novel proteases cleave influenza virus 
hemagglutinin from different viral subtypes (Fig 3A, B, C). Microscopic analysis of the 
cellular localization of TTSPs and colocalization with influenza virus hemagglutinin (Fig. 
6A) and calculation of the Person correlation coefficient (Fig. 6B). Production of lentiviral 
vectors bearing the influenza hemagglutin/neuraminidase and analysis of the HA activation in 
transduced cells (Fig. 7A). Propagation of influenza viruses in chorioallantoic fluid of 
embryonated hen eggs and analysis of the proteolytic activation of hemagglutinin by type II 
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Design and conduct of the experiments. Construction of TMPRSS2/TMPRSS3 chimeras (Fig. 
1A).  Analysis of TTSPs chimeras expression via Western blotting (Fig. 1B). Determination 
whether constructed chimeras cleave HA (Fig. 2A) and whether cleavage results in the virus 
activation (Fig. 2B).  Analysis of coronavirus S protein cleavage (Fig. 3A) and activation for 
virus-cell fusion (Fig. 3B). Determination of the role of stem region in the HA cleavage and 
activation (Fig. 4). Analysis of TMPRSS4/TMPRSS3 chimeras expression and activity (Fig. 
5). The microscopic analysis of HA and TTSPs chimeras cellular localization (Fig. 6). 
Identification of stem region inhibitor (Fig. 7). Writing parts of the manuscript (Material and 
Methods, Results) 
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ABSTRACT 
The type II transmembrane serine protease (TTSP) TMPRSS2 activates the influenza A virus 
hemagglutinin (FLUAV HA) and coronavirus spike proteins (CoV S) by proteolytic cleavage 
and is essential for FLUAV spread and pathogenesis in mice. In addition, several related TTSPs 
activate HA in cell culture while other enzymes of the same family are inactive, despite an 
identical domain organization and up to 40 % sequence homology. Here, we asked which 
domains in TTSPs determine cleavage and activation of viral glycoproteins. Analysis of 
chimeric proteases revealed that the stem domain determines whether TTSPs can cleave and 
activate HA and CoV S proteins. Moreover, confocal microscopy provided evidence that the 
stem domain controls HA activation by determining protease colocalization with HA. Finally, 
we found that HA activation by TTSPs containing a scavenger receptor A (SR-A) domain in 
their stem region can be inhibited by dextran sulphate, a known SR-A ligand. These results 
identify the stem domain of TTSPs as a key determinant of proteolytic processing of viral 
glycoproteins and possibly other ligands. Moreover, our findings provide evidence that the SR-
A domain within the stem is a target for intervention, which has implications for the 
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IMPORTANCE 
The efficacy of antivirals for treatment of influenza is compromised by viral resistance. The 
inhibition of cellular factors essential for influenza virus replication might suppress viral spread 
without inducing resistance development. The cellular protease TMPRSS2 is a potential target: 
TMPRSS2 activates the influenza virus hemagglutinin (HA) and is essential for viral 
pathogenesis in mice. The successful exploitation of TMPRSS2 for antiviral therapy requires a 
thorough understanding of how TMPRSS2 recognizes HA. Here, we show that the stem region 
of TMPRSS2 is the key determinant of HA activation, because it controls the ability of 
TMPRSS2 to colocalize with HA. Moreover, we provide evidence that HA activation can be 
blocked by inhibitors targeting a scavenger receptor domain located in the stem region. These 
findings identify the stem region as a major determinant of ligand recognition by TMPRSS2 
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INTRODUCTION 
The ability of influenza A viruses (FLUAV) to constantly adapt to immune pressure results in 
annually recurring influenza epidemics, which pose a significant health threat, in particular to infants 
and the elderly: 250 000 to 500 000 annual deaths are attributed to influenza epidemics and are 
associated with costs of 87.1 billion USD per year in the US alone (1, 2). Moreover, the introduction 
of new FLUAV into the human population or the reassortment of human and animal FLUAV may 
result in influenza pandemics with potentially devastating consequences, as exemplified by the 
pandemic in 1918, which is believed to have claimed 30 to 50 million lives (3). Preventive and 
therapeutic options against influenza are in place (4, 5) but have significant shortcomings: 
Vaccination protects against epidemic but not pandemic influenza and currently available 
therapeutics, which target the viral proteins neuraminidase and M2, are plagued by frequent 
emergence of resistant viruses (6). Therefore, new therapeutic options against FLUAV have to be 
devised which display a high barrier against resistance development and host cell factors which are 
essential for viral spread but dispensable for cellular survival are attractive targets for such 
endeavours. 
  The FLUAV hemagglutinin (HA) protein is inserted into the viral envelope and facilitates 
infectious viral entry into target cells (7). HA is generated as an inactive precursor protein in the 
constitutive secretory pathway of infected cells and is only converted into its active form upon 
processing by host cell proteases (8, 9). Consequently, the activity of the responsible proteases is 
essential for viral infectivity. It has long been believed that a multitude of proteases secreted into the 
lung lumen facilitate HA activation in the host (10, 11). However, recent studies demonstrate that the 
type II transmembrane serine protease TMPRSS2 activates FLUAV upon directed and endogenous 
expression (12-14), that TMPRSS2 is expressed in susceptible cells in the human aerodigestive tract 
(15) and that TMPRSS2 is essential for FLUAV spread and pathogenesis in mice (16-18). Moreover, 
polymorphisms in TMPRSS2 which increase protease expression were found to be associated with 
susceptibility to severe influenza (19). Finally, several studies indicate that viruses other than 
FLUAV, including SARS- and MERS-coronavirus (SARS-CoV, MERS-COV) (20-24) and hepatitis 
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C virus (25) can be activated by TMPRSS2. Collectively, TMPRSS2 is a host factor essential for 
spread of FLUAV and potentially other viruses but is dispensable for normal development and 
homeostasis (26) and thus constitutes an attractive target for therapeutic intervention. 
  Cell culture studies revealed that several TTSPs other than TMPRSS2 can activate HA, 
including HAT, TMPRSS4, DESC1 and MSPL (14, 27, 28), and it is at present unclear whether these 
enzymes can contribute to viral spread in the host under certain conditions. Moreover, more than 8 
TTSPs were identified which failed to activate HA despite robust expression in cell culture (12, 28) 
and despite exhibiting the same domain organization as TMPRSS2 as well as considerable sequence 
homology. For instance, TMPRSS3, like TMPRSS2, contains a cytoplasmic, transmembrane, stem 
and protease domain and the protease domains of these two enzymes share 71% amino acid 
homology. Still, TMPRSS3 fails to activate HA in cells engineered to express high levels of the 
protease (12, 28). Therefore, we investigated which domains in TTSPs determine the ability to 
activate HA and we asked if this domain/these domains can be targeted for antiviral intervention. 
  Our results show that the stem region in TTSPs determines HA activation by controlling the 
ability of these enzymes to colocalize with HA. Moreover, we demonstrate that HA activation by 
TTSPs which encode a scavenger receptor A (SR-A) domain in their stem can be inhibited by dextran 
sulphate, a known ligand of SR-A (29, 30). Our results define the stem region as a central determinant 
of FLUAV activation and ligand specificity of TTSPs and might have implications for the 






Page | 47  
 
MATERIALS AND METHODS 
 
Cell culture. The cell lines 293T, Calu-3, Caco-2  and COS-7 were grown in Dulbecco’s modified 
Eagle’s medium (DMEM, PAN Biotech) while MDCK cells were grown in minimum essential 
medium (MEM, Gibco). All media were supplemented with 10% fetal bovine serum (FBS, 
Biochrome) and 100 U/ml penicillin and streptomycin (PAN Biotech). 
 
Plasmids. The plasmids encoding TMPRSS2, TMPRSS3, TMPRSS4, HA of subtype H1 and H3, the 
spike (S) proteins of SARS-CoV (SARS-S) and MERS-CoV (MERS-S), ACE2 and DPP4 were 
described previously (12, 20, 21, 28). Chimeric proteases with and without N-terminal myc antigenic 
tag were constructed using overlap extension PCR. PCR amplicons were cloned into pCAGGS (31) 
via EcoRI, XhoI (TMPRSS2/TMPRSS3 chimeras) and KpnI, XhoI (TMPRSS4/TMPRSS3 chimeras) 
and the sequences were verified by automated sequencing. Detailed cloning strategies as well as 
primer sequences are available upon request. 
 
TTSP expression and autocatalytic activation. For analysis of expression and autocatalytic 
activation of TTSP chimeras, the plasmids encoding the proteases equipped with an N-terminal myc 
tag or empty plasmid as a control were transiently transfected into 293T cells, previously seeded into 
6-well plates at a density of 2.8 x 10
5
 cells/well. After overnight incubation, the medium was replaced 
with fresh DMEM and at 48 h post transfection the cells were washed with phosphate-buffered saline 
(PBS), resuspended in 100 µl of 2 x sodium dodecyl sulphate (SDS) loading buffer per well and then 
heated at 95°C for 30 min. Protein samples were separated by SDS-PAGE, and blotted onto a 
nitrocellulose membrane (Hartenstein). Protease expression was detected using a mouse anti-myc 
antibody (Biomol) as the primary antibody and a horseradish peroxidase (HRP)-coupled antibody 
(Dianova) as the secondary antibody. Expression of β-actin, detected with anti-β-actin antibody 
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(Sigma Aldrich), served as a loading control. A commercially available ECL Prime Western blotting 
detection kit (Amersham) was used to detect the bound antibodies and the image acquisition was 
performed with a ChemoCam Imager (Intas). 
 
Cleavage of viral glycoproteins by TTSPs. To determine cleavage of FLUAV HA by wt and 
chimeric TTSPs, 293T cells were seeded in 6-well plates at a concentration of 2.8 x10
5
 cells/well and 
cultured for 24 h. Subsequently, the cells were cotransfected with 6 µg of plasmid encoding FLUAV 
HA of the H1 or H3 subtype and 0.3 µg of plasmid encoding the indicated proteases, employing the 
calcium phosphate transfection protocol. At 16 h post transfection, the medium was changed and at 48 
h post transfection the cells were harvested in PBS, treated with PBS or 250 µg/ml tosylsulfonyl 
phenylalanyl chloromethyl ketone (TPCK) treated trypsin (Sigma Aldrich) for 10 min at 37°C and 
processed for Western blot analysis as described above. FLUAV HA of the H1 subtype was detected 
with a goat anti-FLUAV polyclonal antibody (Milipore) while HA of the H3 subtype was detected 
with rabbit anti-H3 HA serum (Immune Technology).  
For analysis of SARS-S and MERS-S cleavage by TTSPs, 293T cells were seeded in 6-well 
plates at a concentration of 2.88 x 10
5
 cells/well, cultured for 24 h and then calcium-phosphate 
transfected with 6 µg of plasmid encoding SARS-S and MERS-S, both equipped with a C terminal V5 
tag. Simultaneously, 293T cells were prepared in the same way and were transfected with empty 
plasmid (pCAGGS) or plasmids encoding ACE2 or DPP4, respectively, and the proteases. At 16 h 
post transfection the medium was changed and at 24 h post transfection S protein and 
receptor/protease expressing cells mixed, cultivated for 24, treated with PBS or TPCK trypsin and 
processed for Western blot analysis as described above. SARS-S and MERS-S were detected by 
staining with mouse monoclonal antibody reactive against the V5 tag (Invitrogen), followed by 
incubation with an HRP-coupled anti-mouse secondary antibody (Dianova).  
To analyze cleavage inhibition by dextran sulphate, an SR-A inhibitor (29, 30), 293T cells 
were transfected with plasmids encoding HA and proteases, as described above. At 8 h post 
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transfection, the medium was replaced with fresh DMEM supplemented with PBS, 100 µg/ml dextran 
sulphate (Sigma Aldrich) or 100 µg/ml chondroitin sulphate (Sigma Aldrich). At 48 h post 
transfection the cells were harvested and processed for Western blot analysis as described above. The 
quantification of HA cleavage was performed with Fiji software (32).  
 
FLUAV production and infection experiments. A/PR/8/34 (H1N1) was obtained from collaborators 
and was previously described (16). A/Panama/2007/99 (H3N2) was reconstituted from a previously 
described 8-plasmid system (33). Both viruses were propagated in the chorio-allantoic cavity of 10-
day-old embryonated hen eggs (Valo Biomedia Gmbh, Germany) for 48 h at 37°C. Thereafter, the 
eggs were chilled overnight at 4 °C and the allantoic fluid was harvested. For infection experiments, 
293T cells were seeded in 12-well plates at a density of 1.4 × 10
5
 cells/well. After 24 h, the cells were 
transfected with 3 µg expression plasmids encoding the indicated proteases or empty plasmid using 
the calcium phosphate transfection method. The transfection medium was replaced by fresh medium 
after an overnight incubation. At 24 h post transfection, the culture medium was removed and the 
cells incubated with infection medium (DMEM supplemented with 0,2% BSA) containing A/PR/8/34 
(H1N1) at an MOI of 0.01 or A/Panama/2007/99 (H3N2) at an MOI of 0.1. After 1 h of incubation at 
37°C, the infection medium was removed, the cells were gently washed with PBS and fresh infection 
medium was added. Culture supernatants were collected at 48 h post infection and the infectious units 
were quantified by focus formation assay, as described below. To assess inhibition of TTSPs by 
dextran sulphate and chondroitin sulphate, as control, the 293T cells were transfected with indicated 
proteases and infected with A/PR/8/34 (H1N1) at an MOI of 0.01, as described above. After infection, 
the medium was replaced with fresh infection medium supplemented with PBS, 100 µg/ml dextran 
sulphate sodium salt (Sigma Aldrich) or 100 µg/ml chondroitin sulfate A sodium salt from bovine 
trachea (Sigma Aldrich) and infectivity in culture supernatants was determined at 48 h post infection. 
To assess inhibition of FLUAV in Caco-2 or Calu-3 cells, which express endogenous TMPRSS2 (12, 
13), the cells were seeded in 12-well plates at a density of 1.4 × 10
5
 cells/well. After 24 h, the cells 
were infected with A/PR/8/34 (H1N1) at an MOI of 0.01, as described above. After 1h of incubation 
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with virus, the cells were washed with PBS and fresh infection medium supplemented with increasing 
amount of dextran sulphate or chondroitin sulphate was added. Culture supernatants were collected at 
48 h post infection. 
 
Focus formation assay. The infectious units within culture supernatants were quantified by focus 
formation assay, as described previously (34). In brief, serial 5-fold dilution of samples were prepared 
in infection medium (DMEM with 1% P/S and 0.1% BSA) and added to MDCK cells. After 1 h of 
incubation, the medium was replaced by infection medium containing Avicel overlay and 2.5 µg/ml 
N-acetylated trypsin (Sigma), and the cells were incubated for 24 h. Subsequently, the cells were 
fixed with 4% formalin in PBS, and incubated for 1 h with anti-FLUAV (Milipore), followed by 1 h 
incubation with anti-goat-HRP antibodies (Dianova), and 10 min incubation with True Blue substrate 
(KPL). Foci were counted and viral titers were calculated as focus forming units (FFU) per ml of 
culture supernatant. 
 
Colocalization of HA and TTSPs. The colocalization of TTSPs and HA was determined as described 
previously (28). In brief, COS-7 cells were transiently transfected with 6 µg of plasmids encoding the 
indicated proteases equipped with N-terminal myc tag or empty plasmid as control. After overnight 
incubation, the transfection medium was replaced with fresh DMEM, and at 24 h post transfection, 





with 0.2% BSA, containing FLUAV A/PR/8/34 at an MOI 0.5. Thereafter, the cells were washed with 
PBS and fresh infection medium was added. At 24 h post infection, the cells were fixed with ice cold 
methanol, blocked with 3% BSA for 1h, and then stained with mouse anti-myc and rabbit anti-PR8 
HA antibodies (Biomol and Sino Biological, respectively). After 1 h of incubation with primary 
antibodies, the cells were washed three times with PBS and incubated for 1 h with anti-mouse and 
anti-rabbit secondary antibodies, coupled to Rhodamine Red-X and FITC (Dianova), respectively. 
After three final washing steps, the cells were incubated with Vectashield mounting medium (Vector 
Laboratories) and analyzed with a Zeiss LSM 5 laser scanning microscope. Image capture was 
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performed with Pascal Software (Zeiss) and Fiji software was used for image analysis and calculation 
of Pearson Correlation Coefficient. 
 
TTSP-mediated activation of CoV-S proteins for virus-cell fusion. For the analysis of the 
activation of SARS-S and MERS-S for virus-cell fusion, we employed a previously described 
retroviral pseudotyping system (35). Briefly, 293T cells were seeded in a T25 cell culture flask at a 
density of 7.0 x 10
5
 cells/flask, cultured for 24 h and then transfected via calcium phosphate 
precipitation with plasmids encoding for MLV gag-pol (3 µg), a firefly-luciferase harboring MLV 
vector (6 µg), and a plasmid encoding for SARS-S or MERS-S (3 µg). The transfection medium was 
replaced by fresh DMEM after overnight incubation and vector-containing supernatants were 
harvested at 48 h post transfection. Supernatants were passed through a 0.45 µm filter, aliquoted and 
stored at -80°C. For analysis of SARS-S- and MERS-S-mediated entry, 293T cells were transiently 
cotransfected with plasmids encoding the SARS-CoV receptor ACE2 (2 µg) or the MERS-CoV 
receptor CD26 (2 µg) and the indicated proteases (0.3 µg) or an empty plasmid as a control. The 
transfection medium was changed after overnight incubation, the cells were resuspended in fresh 
DMEM and seeded into 96-well plates. At 48 h post transfection, the cells were preincubated with 
dimethyl sulfoxide (DMSO) or 10 µM cathepsin B and L inhibitor MDL 28170 (Calbiochem) for 1 h 
and then incubated with 50 µl of infectivity-normalized pseudotypes for 8 h. Thereafter, 50 µl of fresh 
medium was added and the luciferase activities in cell lysate were determined at 72 h post 










TMPRSS2/TMPRSS3 chimeras are efficiently expressed and autocatalytically activated in 293T 
cells. In order to determine which domains in TTSPs are required for HA proteolytic processing, we 
constructed chimeras between TMPRSS2 (which activates HA) and TMPRSS3 (which fails to 
activate HA) by exchanging the cytoplasmic domain, cytoplasmic and transmembrane domain or 
cytoplasmic, transmembrane and stem domain (Fig 1A). All wild type (wt) and chimeric proteins 
were efficiently expressed in 293T cells and exhibited the expected molecular weights (Fig 1B). 
Moreover, signals for the zymogen form and/or the activated form (protease domain proteolytically 
separated from the stem domain) were detected for each protease (Fig 1B), although the degree of 
activation varied between the chimeras tested. Thus, domain exchange between TMPRSS2 and 
TMPRSS3 is compatible with robust expression and autocatalytic activation. 
 
Cleavage and activation of FLUAV-HA and CoV S proteins by TMPRSS2/TMPRSS3 chimeras. 
We next assessed whether the TMPRSS2/TMPRSS3 chimeras were able to cleave and activate 
FLUAV HA. To assess HA cleavage, we coexpressed proteases and HA of the H1 subtype and 
analyzed HA processing by Western blot. The presence of the HA1 subunit, which indicates 
processing of the HA0 precursor, was observed when cells coexpressed TMPRSS2 wt or were treated 
with trypsin (Fig 2A), as expected. Additionally, HA1 was detected when HA and chimeras 3-2-2-2, 
3-3-2-2 and 2-2-2-3 were coexpressed (Fig 2A). In contrast, TMPRSS3 wt and chimeras 3-3-3-2, 2-3-
3-3 and 2-2-3-3 failed to process HA. In order to assess whether cleavage resulted in activation, the 
protease expressing cells were infected with FLUAV A/PuertoRico/8/34 (H1N1) or 
A/Panama/2007/99 (H3N2) and release of infectious units in culture supernatants was determined. 
TMPRSS2 wt and trypsin treatment facilitated viral spread (Fig 2B,C), as expected. In addition, all 
chimeras able to cleave HA also promoted viral spread while the remaining chimeras were inactive 
(Fig 2B,C). Next, we asked whether cleavage and activation of FLUAV HA reflected that of SARS-S 
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and MERS-S, which are also substrates of TMPRSS2 (20-24). Indeed, TMPRSS2 wt and chimeras 3-
2-2-2, 3-3-2-2 and 2-2-2-3, which were able to process HA, also cleaved and activated SARS-S for 
cathepsin L-independent virus-cell entry, and comparable observations were made for MERS-S (Fig 
3). Inspection of the chimeras which were able to activate FLUAV-HA and CoV S proteins revealed 
that all contained the TMPRSS2 stem domain, suggesting that this domain is an important 
determinant of HA and S protein cleavage and activation by TMPRSS2. 
 
The TMPRSS2 stem domain controls HA cleavage and activation. In order to provide formal 
proof that the stem region of TMPRSS2 controls HA cleavage and activation, we constructed a 
chimera in which the cytoplasmic, transmembrane and catalytic domain originated from TMPRSS3 
while the stem region was derived from TMPRSS2 (chimera 3-3-2-3, Fig 4A). The resulting protein 
was robustly expressed in transfected 293T cells and was activated, since bands with the molecular 
weight expected for the zymogen and for the N-terminal fragment produced upon activation were 
observed (Fig 4B). Importantly, chimera 3-3-2-3 cleaved (Fig 3C) and activated HA (Fig 3D), 
demonstrating that the TMPRSS2 stem domain is a key determinant of HA cleavage and activation. 
 
The TMPRSS4 stem domain controls HA cleavage and activation. To confirm that our findings 
made for TMPRSS2 are also applicable to other members of the TMPRSS/hepsin subfamily of 
TTSPs, we constructed chimeras between TMPRSS4 (which activates FLUAV (27)) and TMPRSS3 
(which fails to activate FLUAV), in which the cytoplasmic, transmembrane and stem domains were 
exchanged, resulting in constructs 4-4-4-3 and 3-3-3-4 (Fig 5A). Western blot analysis demonstrated 
that all proteases analyzed were robustly expressed (Fig 5B). For TMPRSS4 and 4-4-4-3 mainly the 
zymogen forms were detected (with the expected molecular weights of 55 and 53 kDa, respectively) 
while proteolytic processing products predominated in cells expressing TMPRSS3 and 3-3-3-4 (with 
the expected molecular weights of 37 and 37 kDa, respectively) (Fig 5B). TMPRSS4 expression and 
trypsin treatment resulted in the robust production of the HA1 subunit in transfected cells (Fig 5C), as 
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expected, and the same observation was made for chimera 4-4-4-3. In contrast, chimera 3-3-3-4 was 
inactive (Fig 5C). Comparable results were obtained when activation of FLUAV and MERS-S was 
analyzed: TMPRSS4 wt and chimera 4-4-4-3 activated H1N1 (Fig 5D) and H3N2 FLUAV (Fig 5E) as 
well as MERS-S (Fig 5F) for viral spread and S protein-mediated transduction, respectively, while 
TMPRSS3 wt and chimera 3-3-3-4 were inactive. These results demonstrate that the stem domain of 
TMPRSS4 and likely other TTSPs is a central determinant of HA and CoV-S protein activation. 
 
The TMPRSS2 stem region determines protease colocalization with HA. The unexpected finding 
that the stem domain (and not the protease domain) controls cleavage and activation of viral 
glycoproteins raised questions regarding the underlying mechanism. We had previously demonstrated 
that HA-activating TTSPs (i.e. TMPRSS2, DESC1 and MSPL) colocalized with HA at or near to the 
plasma membrane while an inactive TTSP (i.e. TMPRSS3) did not colocalize with HA (28). 
Therefore, we asked whether the TMPRSS2 stem region controls the ability of TMPRSS2/TMPRSS3 
chimeras to activate HA by determining their ability to colocalize with HA. To this end, we expressed 
TMPRSS2, TMPRSS3, 3-3-3-2 and 2-2-2-3 in COS-7 cells, infected the cells with FLUAV and 
employed immunostaining and confocal microscopy to assess colocalization of HA and proteases. We 
found that TMPRSS2 and the HA-activating chimera 2-2-2-3 were present at or near to the cellular 
surface (Fig 6A) and colocalized with FLUAV HA, as demonstrated by a Pearson Correlation 
Coefficient above 0.6 (Fig 6B). In contrast, TMPRSS3 wt and chimera 3-3-3-2, which failed to cleave 
HA, demonstrated a predominantly cytoplasmic localization, and did not colocalize appreciably with 
HA (Fig 6A,B). These results suggest that the stem regions of TMPRSS2 and TMPRSS3 control 
cleavage (or absence thereof) of viral glycoproteins by determining the cellular localization of these 
proteases. 
 
Dextran sulphate suppresses HA activation by TTSPs harboring a scavenger receptor A 
domain. The important role of the stem domain in virus activation raised the question whether this 
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domain is a potential target for antiviral intervention. The stem region of HA activating enzymes of 
the TTSP/Hepsin subfamily, TMPRSS2, TMPRSS4 and hepsin, contains a scavenger receptor A (SR-
A) domain which exhibits up to 60% sequence homology with SR-A (Fig 7A). An antibody targeting 
the SR-A domain in TTSPs was not available but dextran sulphate was previously shown to block 
ligand binding to SR-A (29, 30). Therefore, we asked whether dextran sulphate blocks FLUAV spread 
in cells expressing HA-activating TTSPs containing an SR-A domain. As negative control, we 
employed chondroitin sulphate, which does not interfere with ligand binding to SR-A (36). Moreover, 
cells transfected with DESC1 and HAT – members of the HAT/DESC subfamily of TTSPs, which 
can activate HA but do not contain an SR-A domain – were used as additional negative controls. 
FLUAV infection of the transfected cells revealed that TTSP expression or addition of trypsin to the 
culture medium activated FLUAV for robust spread while spread in cells transfected with empty 
plasmid was inefficient (Fig 7B), as expected. Treatment of cells with chondroitin sulphate before 
addition of virus did not alter viral spread irrespective of the presence of protease. Similarly, dextran 
sulphate did not alter spread in cells transfected with empty plasmid and treated with PBS or trypsin 
or in cells expressing DESC1 and HAT. In contrast, dextran sulphate treatment markedly reduced 
viral spread in cells expressing HA-activating TTSPs containing a SR-A domain (Fig 7B), TMPRSS2, 
TMPRSS4, MSPL and hepsin.  
We next tested whether dextran sulphate inhibits FLULAV spread in Caco-2 and Calu-3 cells, 
which endogenously express TMPRSS2 and thus allow trypsin-independent viral spread (12, 13, 37). 
Dextran sulphate efficiently and dose-dependently reduced viral spread in these cells while 
chondroitin sulphate had not effect (Fig 7C), in keeping with the concept that antiviral activity of 
dextran sulphate may result from blockade of TMPRSS2 or related proteases. In order to obtain direct 
proof for this mechanism of action, we coexpressed HA and TMPRSS4 (contains the SR-A domain) 
or DESC1 (does not contain the SR-A domain) and analyzed HA cleavage by Western blot. Both 
proteases were chosen because their expression results in particularly robust HA cleavage in 
transfected cells. In the absence of protease, only uncleaved HA0 was detected irrespective of the 
presence or absence of chondroitin or dextran sulphate (Fig 7D), in keeping with expectations. 
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Moreover, coexpression of TMPRSS4 and DESC1 resulted in almost complete processing of HA0 
into HA01 (Fig 7D) and HA2 (not detected), again in keeping with expectations, and processing 
efficiency was not altered by treatment of cells with chondroitin sulphate (Fig 7D). In contrast, HA 
cleavage by TMPRSS4 was reproducibly and significantly reduced by dextran sulphate while HA 
processing by DESC1 was increased in the presence of this compound (Fig 7D), demonstrating that 
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DISCUSSION 
TTSPs are plasma membrane-associated serine proteases that process a range of cellular substrates, 
including growth factors and components of the extracellular matrix (38, 39). The observation that 
aberrant expression of TTSPs is associated with several cancers moved these enzymes into the center 
of efforts to identify tumor markers and anti-tumor therapies (38, 39). More recently, it was 
discovered that the glycoproteins of FLUAV and other viruses are substrates of TTSPs (8, 9, 40), 
indicating that these proteases are also potential targets for antiviral intervention. The success of such 
endeavors depends, at least in part, on our understanding of the determinants controlling ligand 
specificity of TTSPs, which are largely unclear. Here, we show that the stem region determines 
whether TTSPs can process viral glycoproteins.  Moreover, our study provides evidence that the SR-
A domain present in the stem of certain TTSPs is a potential target for inhibitors. These findings not 
only provide important insights into ligand recognition by TTSPs but might also afford new 
opportunities to target TTSPs for therapeutic intervention. 
 The TTSP family contains more than 20 members which are grouped into four subfamilies, 
Hepsin/TMPRSS, Matriptase, Corin and HAT/DESC (38, 39). TTSPs which activate HA in cell 
culture are found in the TMPRSS/hepsin family (TMPRSS2, TMPRSS4, hepsin and MSPL, (12, 14, 
28)), the Matriptase subfamily (matriptase (41-43)) and the HAT/DESC family (HAT, DESC1 (14, 
28)). TMPRSS2 activates diverse viruses in cell culture and expression of the protease in rodents is 
critical for spread and pathogenesis of FLUAV (16-18) and potentially also SARS-CoV (44). 
Nevertheless, other TTSPs might contribute to viral activation under certain conditions. Thus, several 
members of the TTSP family were found to activate viruses in cell culture (14, 27, 28, 41-43) and 
these enzymes might contribute to the activation of recently identified viruses with reduced or absent 
TMPRSS2-dependence (16, 45). In contrast, a panel of other TTSPs was found to be unable to 
activate viruses, despite robust expression in cultured cells (28), raising the question which properties 
of TTSPs determine specificity for viral glycoproteins. 
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We employed chimeric TTSPs to identify determinants of ligand recognition. The stepwise 
substitution of the cytoplasmic, transmembrane and stem domain of TMPRSS2 by the corresponding 
domains of TMPRSS3 and vice versa pointed towards a key role of the stem in HA cleavage and 
activation. This conclusion was further supported by the analysis of TMPRSS3/TMPRSS4 chimeras 
and by the demonstration that replacing the TMPRSS3 stem by that of TMPRSS2 is sufficient to 
render the chimeric enzyme capable of HA cleavage and activation. How is the stem region organized 
and how does it impact ligand recognition? The stem region of TTSPs can harbor up to 11 domains 
derived from 6 proteins, including SR-A, and is known to impact zymogen activation and sensitivity 
of TTSPs to protease inhibitors (38, 39). Moreover, a role for the stem region in the proteolytic 
processing of ligands has been reported: a frizzled 1 domain and LDLR repeats with the stem region 
of corin were shown to be essential for processing of a physiological substrate, pro-ANP (46), while 
the stem region of enteropeptidase was found to be required for processing of macromolecules but not 
small peptides (47). However, the underlying mechanism remained unclear.  
It is conceivable that the stem region impacts ligand recognition by ensuring the adequate 
spatial presentation of the catalytic domain and such a structural role has been proposed for the stem 
of corin (46). Our study suggests a second possibility: The stem might determine whether a TTSP 
comes into contact with a potential ligand by controlling the cellular localization of the enzyme. Thus, 
the stem region of FLUAV activating TTSPs was found to be required for colocalization with HA at 
or close to the cell surface, the site where HA is believed to be activated by TTSPs. This finding is in 
line with our previous observation that the ability of TTSPs to activate HA correlates with their 
capacity to colocalize with this protein (28). Our observations are also in keeping with the concept 
that the stem might impact TTSP trafficking within cells, which has been posited in review articles 
(38, 39), but for which, to our knowledge, direct experimental evidence is missing. In sum, the stem 
determines whether TTSPs colocalize with HA and this raises the question whether this domain is a 
target for inhibitors. 
The stem regions of TMPRSS2 and TMPRSS3 contain a single protein domain, which 
exhibits 58 and 61 %, respectively, homology with the scavenger receptor cysteine-rich domain 
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(SRCR) of SR-A. The SRCR facilitates binding of SR-A to a variety of modified proteins and lipids 
of cellular origin as well as to pathogen-associated molecular patterns (PAMPs) and clears these 
ligands from the circulation (48). Dextran sulfate, a polyanion, is a well-established inhibitor of ligand 
binding to SR-A (29, 30) and was therefore used to probe whether targeting the SR-A domain in 
TTSPs inhibits FLUAV activation. Indeed, dextran sulfate treatment selectively inhibited FLUAV 
activation by TTSPs containing a SR-A domain while chondroitin sulfate, which fails to inhibit ligand 
binding to SR-A (36), did not exert inhibitory activity. In addition, dextran sulfate modestly reduced 
HA processing by TMPRSS4 (which contains an SR-A domain) but not DESC1 (which does not 
contain an SR-A domain) in HA transfected cells, indicating that inhibition of FLUAV spread by 
dextran sulfate was due to blockade of HA activation. In this context, it should be noted that treatment 
of cells with camostat mesylate, which blocks activation of viruses by TTSPs with high efficiency 
(20, 23, 44, 49, 50), also had only moderate effects on HA cleavage in transfected cells (data not 
shown). Thus, the very high levels of HA and TTSP expression in transfected 293T cells may 
preclude visualizing efficient inhibition of HA cleavage. Finally, it is noteworthy that dextran sulphate 
was previously shown to inhibit A/PR/8/34 spread in MDCK cells in an NA-dependent fashion (51). 
Why similar effects were not observed in the present study (conduced with 293T cells) is at present 
unclear, and cell type specific differences might be accountable. In sum, we obtained evidence that 
dextran sulphate can block TTSP-dependent HA activation by targeting the SR-A domain within the 
stem of certain TTSPs. 
Collectively, our study identifies the TMPRSS2 stem as the key determinant of activation of 
viral glycoproteins and as a potential target for intervention. Evidence is accumulating that TMPRSS2 
is essential for spread of respiratory viruses and inhibitors which target TMPRSS2 along with many 
other proteases have been shown to display antiviral activity in the host (52, 53). The goal of future 
research endeavors should thus be the development of inhibitors specific for TMPRSS2 and the 
discovery of the stem region as a target for intervention should aid these efforts. 
 
Page | 60  
 
ACKNOWLEDGEMENTS 
We thank S. Bertram for valuable discussion and DFG (PO 716/6-1) and the Leibniz 
Association (Graduate School Emerging Infectious Diseases) for funding. This work  was 
partly supported by the Göttingen Graduate School for Neurosciences, Biophysics and 





















 1.  Molinari, N. A., I. R. Ortega-Sanchez, M. L. Messonnier, W. W. Thompson, P. M. 
Wortley, E. Weintraub, and C. B. Bridges. 2007. The annual impact of seasonal influenza 
in the US: measuring disease burden and costs. Vaccine 25:5086-5096. 
 2.  WHO. Influenza (Seasonal).  http://www.who.int/mediacentre/factsheets/fs211/en/ 
3.   Johnson, N. P. and J. Mueller. 2002. Updating the accounts: global mortality of the 1918-
1920 "Spanish" influenza pandemic. Bull. Hist Med. 76:105-115. 
 4.  Krammer, F. and P. Palese. 2015. Advances in the development of influenza virus vaccines. 
Nat. Rev. Drug Discov. 14:167-182. 
 5.  Loregian, A., B. Mercorelli, G. Nannetti, C. Compagnin, and G. Palu. 2014. Antiviral 
strategies against influenza virus: towards new therapeutic approaches. Cell Mol. Life Sci. 
71:3659-3683. 
 6.  Hurt, A. C. 2014. The epidemiology and spread of drug resistant human influenza viruses. 
Curr. Opin. Virol. 8:22-29. 
 7.  Edinger, T. O., M. O. Pohl, and S. Stertz. 2014. Entry of influenza A virus: host factors and 
antiviral targets. J. Gen. Virol. 95:263-277. 
 8.  Bertram, S., I. Glowacka, I. Steffen, A. Kuhl, and S. Pohlmann. 2010. Novel insights into 
proteolytic cleavage of influenza virus hemagglutinin. Rev. Med. Virol. 20:298-310. 
 9.  Bottcher-Friebertshauser, E., H. D. Klenk, and W. Garten. 2013. Activation of influenza 
viruses by proteases from host cells and bacteria in the human airway epithelium. Pathog. Dis. 
69:87-100. 
 10.  Kido, H., Y. Yokogoshi, K. Sakai, M. Tashiro, Y. Kishino, A. Fukutomi, and N. 
Katunuma. 1992. Isolation and characterization of a novel trypsin-like protease found in rat 
bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J. Biol. 
Chem. 267:13573-13579. 
 11.  Kido, H., Y. Okumura, H. Yamada, T. Q. Le, and M. Yano. 2007. Proteases essential for 
human influenza virus entry into cells and their inhibitors as potential therapeutic agents. 
Curr. Pharm. Des 13:405-414. 
 12.  Bertram, S., I. Glowacka, P. Blazejewska, E. Soilleux, P. Allen, S. Danisch, I. Steffen, S. 
Y. Choi, Y. Park, H. Schneider, K. Schughart, and S. Pohlmann. 2010. TMPRSS2 and 
TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J. Virol. 
84:10016-10025. 
 13.  Bottcher-Friebertshauser, E., D. A. Stein, H. D. Klenk, and W. Garten. 2011. Inhibition 
of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated 
morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. J. Virol. 
85:1554-1562. 
Page | 62  
 
 14.  Bottcher, E., T. Matrosovich, M. Beyerle, H. D. Klenk, W. Garten, and M. Matrosovich. 
2006. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT 
from human airway epithelium. J. Virol. 80:9896-9898. 
 15.  Bertram, S., A. Heurich, H. Lavender, S. Gierer, S. Danisch, P. Perin, J. M. Lucas, P. S. 
Nelson, S. Pohlmann, and E. J. Soilleux. 2012. Influenza and SARS-coronavirus activating 
proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and 
gastrointestinal tracts. PLoS. One. 7:e35876. 
 16.  Hatesuer, B., S. Bertram, N. Mehnert, M. M. Bahgat, P. S. Nelson, S. Pohlman, and K. 
Schughart. 2013. Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice. 
PLoS. Pathog. 9:e1003774. 
 17.  Sakai, K., Y. Ami, M. Tahara, T. Kubota, M. Anraku, M. Abe, N. Nakajima, T. 
Sekizuka, K. Shirato, Y. Suzaki, A. Ainai, Y. Nakatsu, K. Kanou, K. Nakamura, T. 
Suzuki, K. Komase, E. Nobusawa, K. Maenaka, M. Kuroda, H. Hasegawa, Y. Kawaoka, 
M. Tashiro, and M. Takeda. 2014. The Host Protease TMPRSS2 Plays a Major Role in In 
Vivo Replication of Emerging H7N9 and Seasonal Influenza Viruses. J. Virol. 88:5608-5616. 
 18.  Tarnow, C., G. Engels, A. Arendt, F. Schwalm, H. Sediri, A. Preuss, P. S. Nelson, W. 
Garten, H. D. Klenk, G. Gabriel, and E. Bottcher-Friebertshauser. 2014. TMPRSS2 Is a 
Host Factor That Is Essential for Pneumotropism and Pathogenicity of H7N9 Influenza A 
Virus in Mice. J. Virol. 88:4744-4751. 
 19.  Cheng, Z., J. Zhou, K. K. To, H. Chu, C. Li, D. Wang, D. Yang, S. Zheng, K. Hao, Y. 
Bosse, M. Obeidat, C. A. Brandsma, Y. Q. Song, Y. Chen, B. J. Zheng, L. Li, and K. Y. 
Yuen. 2015. Identification of TMPRSS2 as a Susceptibility Gene for Severe 2009 Pandemic 
A(H1N1) Influenza and A(H7N9) Influenza. J. Infect. Dis. 
 20.  Gierer, S., S. Bertram, F. Kaup, F. Wrensch, A. Heurich, A. Kramer-Kuhl, K. Welsch, 
M. Winkler, B. Meyer, C. Drosten, U. Dittmer, H. T. von, G. Simmons, H. Hofmann, 
and S. Pohlmann. 2013. The spike protein of the emerging betacoronavirus EMC uses a 
novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by 
neutralizing antibodies. J. Virol. 87:5502-5511. 
 21.  Glowacka, I., S. Bertram, M. A. Muller, P. Allen, E. Soilleux, S. Pfefferle, I. Steffen, T. 
S. Tsegaye, Y. He, K. Gnirss, D. Niemeyer, H. Schneider, C. Drosten, and S. Pohlmann. 
2011. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus 
spike protein for membrane fusion and reduces viral control by the humoral immune 
response. J. Virol. 85:4122-4134. 
 22.  Matsuyama, S., N. Nagata, K. Shirato, M. Kawase, M. Takeda, and F. Taguchi. 2010. 
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the 
transmembrane protease TMPRSS2. J. Virol. 84:12658-12664. 
 23.  Shirato, K., M. Kawase, and S. Matsuyama. 2013. Middle East respiratory syndrome 
coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 
87:12552-12561. 
Page | 63  
 
 24.  Shulla, A., T. Heald-Sargent, G. Subramanya, J. Zhao, S. Perlman, and T. Gallagher. 
2011. A transmembrane serine protease is linked to the severe acute respiratory syndrome 
coronavirus receptor and activates virus entry. J. Virol. 85:873-882. 
 25.  Esumi, M., M. Ishibashi, H. Yamaguchi, S. Nakajima, Y. Tai, S. Kikuta, M. Sugitani, T. 
Takayama, M. Tahara, M. Takeda, and T. Wakita. 2015. Transmembrane serine protease 
TMPRSS2 activates hepatitis C virus infection. Hepatology 61:437-446. 
 26.  Kim, T. S., C. Heinlein, R. C. Hackman, and P. S. Nelson. 2006. Phenotypic analysis of 
mice lacking the Tmprss2-encoded protease. Mol. Cell Biol. 26:965-975. 
 27.  Chaipan, C., D. Kobasa, S. Bertram, I. Glowacka, I. Steffen, T. S. Tsegaye, M. Takeda, 
T. H. Bugge, S. Kim, Y. Park, A. Marzi, and S. Pohlmann. 2009. Proteolytic activation of 
the 1918 influenza virus hemagglutinin. J. Virol. 83:3200-3211. 
 28.  Zmora, P., P. Blazejewska, A. S. Moldenhauer, K. Welsch, I. Nehlmeier, Q. Wu, H. 
Schneider, S. Pohlmann, and S. Bertram. 2014. DESC1 and MSPL activate influenza A 
viruses and emerging coronaviruses for host cell entry. J. Virol. 88:12087-12097. 
 29.  Goldstein, J. L., Y. K. Ho, S. K. Basu, and M. S. Brown. 1979. Binding site on 
macrophages that mediates uptake and degradation of acetylated low density lipoprotein, 
producing massive cholesterol deposition. Proc. Natl. Acad. Sci. U. S. A 76:333-337. 
 30.  Tsubamoto, Y., N. Yamada, Y. Watanabe, T. Inaba, M. Shiomi, H. Shimano, T. Gotoda, 
K. Harada, M. Shimada, J. Ohsuga, and . 1994. Dextran sulfate, a competitive inhibitor for 
scavenger receptor, prevents the progression of atherosclerosis in Watanabe heritable 
hyperlipidemic rabbits. Atherosclerosis 106:43-50. 
 31.  Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression 
transfectants with a novel eukaryotic vector. Gene 108:193-199. 
 32.  Schindelin, J., I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. 
Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J. Y. Tinevez, D. J. White, V. Hartenstein, 
K. Eliceiri, P. Tomancak, and A. Cardona. 2012. Fiji: an open-source platform for 
biological-image analysis. Nat. Methods 9:676-682. 
 33.  Matthaei, M., M. Budt, and T. Wolff. 2013. Highly pathogenic H5N1 influenza A virus 
strains provoke heterogeneous IFN-alpha/beta responses that distinctively affect viral 
propagation in human cells. PLoS. One. 8:e56659. 
 34.  Winkler, M., S. Bertram, K. Gnirss, I. Nehlmeier, A. Gawanbacht, F. Kirchhoff, C. 
Ehrhardt, S. Ludwig, M. Kiene, A. S. Moldenhauer, U. Goedecke, C. B. Karsten, A. 
Kuhl, and S. Pohlmann. 2012. Influenza A virus does not encode a tetherin antagonist with 
Vpu-like activity and induces IFN-dependent tetherin expression in infected cells. PLoS. One. 
7:e43337. 
 35.  Wrensch, F., M. Winkler, and S. Pohlmann. 2014. IFITM proteins inhibit entry driven by 
the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms. 
Viruses. 6:3683-3698. 
Page | 64  
 
 36.  Bowdish, D. M., K. Sakamoto, M. J. Kim, M. Kroos, S. Mukhopadhyay, C. A. Leifer, K. 
Tryggvason, S. Gordon, and D. G. Russell. 2009. MARCO, TLR2, and CD14 are required 
for macrophage cytokine responses to mycobacterial trehalose dimycolate and 
Mycobacterium tuberculosis. PLoS. Pathog. 5:e1000474. 
 37.  Zhirnov, O. and H. D. Klenk. 2003. Human influenza A viruses are proteolytically activated 
and do not induce apoptosis in CACO-2 cells. Virology 313:198-212. 
 38.  Antalis, T. M., T. H. Bugge, and Q. Wu. 2011. Membrane-anchored serine proteases in 
health and disease. Prog. Mol. Biol. Transl. Sci. 99:1-50. 
 39.  Szabo, R. and T. H. Bugge. 2011. Membrane-anchored serine proteases in vertebrate cell 
and developmental biology. Annu. Rev. Cell Dev. Biol. 27:213-235. 
 40.  Garten, W., C. Braden, A. Arendt, C. Peitsch, J. Baron, Y. Lu, K. Pawletko, K. Hardes, 
T. Steinmetzer, and E. Bottcher-Friebertshauser. 2015. Influenza virus activating host 
proteases: Identification, localization and inhibitors as potential therapeutics. Eur. J. Cell Biol. 
 41.  Baron, J., C. Tarnow, D. Mayoli-Nussle, E. Schilling, D. Meyer, M. Hammami, F. 
Schwalm, T. Steinmetzer, Y. Guan, W. Garten, H. D. Klenk, and E. Bottcher-
Friebertshauser. 2013. Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of 
H9N2 influenza A viruses. J. Virol. 87:1811-1820. 
 42.  Beaulieu, A., E. Gravel, A. Cloutier, I. Marois, E. Colombo, A. Desilets, C. Verreault, R. 
Leduc, E. Marsault, and M. V. Richter. 2013. Matriptase proteolytically activates influenza 
virus and promotes multicycle replication in the human airway epithelium. J. Virol. 87:4237-
4251. 
 43.  Hamilton, B. S., D. W. Gludish, and G. R. Whittaker. 2012. Cleavage activation of the 
human-adapted influenza virus subtypes by matriptase reveals both subtype and strain 
specificities. J. Virol. 86:10579-10586. 
 44.  Zhou, Y., P. Vedantham, K. Lu, J. Agudelo, R. Carrion, Jr., J. W. Nunneley, D. 
Barnard, S. Pohlmann, J. H. McKerrow, A. R. Renslo, and G. Simmons. 2015. Protease 
inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 116:76-84. 
 45.  Sakai, K., T. Sekizuka, Y. Ami, N. Nakajima, M. Kitazawa, Y. Sato, K. Nakajima, M. 
Anraku, T. Kubota, K. Komase, K. Takehara, H. Hasegawa, T. Odagiri, M. Tashiro, M. 
Kuroda, and M. Takeda. 2015. A mutant H3N2 influenza virus uses an alternative 
activation mechanism in TMPRSS2 knockout mice by loss of an oligosaccharide in the 
hemagglutinin stalk region. J. Virol. 89:5154-5158. 
 46.  Knappe, S., F. Wu, M. R. Madlansacay, and Q. Wu. 2004. Identification of domain 
structures in the propeptide of corin essential for the processing of proatrial natriuretic 
peptide. J. Biol. Chem. 279:34464-34471. 
 47.  Lu, D., X. Yuan, X. Zheng, and J. E. Sadler. 1997. Bovine proenteropeptidase is activated 
by trypsin, and the specificity of enteropeptidase depends on the heavy chain. J. Biol. Chem. 
272:31293-31300. 
Page | 65  
 
 48.  Canton, J., D. Neculai, and S. Grinstein. 2013. Scavenger receptors in homeostasis and 
immunity. Nat. Rev. Immunol. 13:621-634. 
 49.  Bertram, S., R. Dijkman, M. Habjan, A. Heurich, S. Gierer, I. Glowacka, K. Welsch, M. 
Winkler, H. Schneider, H. Hofmann-Winkler, V. Thiel, and S. Pohlmann. 2013. 
TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry 
and is expressed in viral target cells in the respiratory epithelium. J. Virol. 87:6150-6160. 
 50.  Zhirnov, O. P., H. D. Klenk, and P. F. Wright. 2011. Aprotinin and similar protease 
inhibitors as drugs against influenza. Antiviral Res. 92:27-36. 
 51.  Yamada, H., E. Moriishi, A. M. Haredy, N. Takenaka, Y. Mori, K. Yamanishi, and S. 
Okamoto. 2012. Influenza virus neuraminidase contributes to the dextran sulfate-dependent 
suppressive replication of some influenza A virus strains. Antiviral Res. 96:344-352. 
 52.  Hosoya, M., S. Matsuyama, M. Baba, H. Suzuki, and S. Shigeta. 1992. Effects of protease 
inhibitors on replication of various myxoviruses. Antimicrob. Agents Chemother. 36:1432-
1436. 
 53.  Lee, M. G., K. H. Kim, K. Y. Park, and J. S. Kim. 1996. Evaluation of anti-influenza 

















FIG 1 Expression and autocatalytic activation of TMPRSS2/TMPRSS3 chimeras. (A) Schematic 
representation of the chimeras between TMPRSS2 and TMPRSS3, which were analyzed in the 
present study. (B) Plasmids encoding the indicated proteases equipped with an N-terminal myc-tag 
were transfected into 293T cells. Transfection of empty plasmid (pCAGGS) served as negative 
control. Protease expression in cell lysates was detected by Western blot using anti-myc antibody. 
Detection of β-actin served as loading control. Similar results were obtained in three separate 
experiments. Black-filled arrowheads indicate zymogen forms, while grey-filled arrowheads highlight 
cleavage products resulting from proteolytic activation. 
 
FIG 2 The chimera 2-2-2-3 cleaves and activates the FLUAV hemagglutinin. (A) Expression plasmids 
encoding the FLUAV HA subtype H1 and the indicated proteases or empty plasmid (pCAGGS) were 
cotransfected into 293T cells. The cells were then treated with PBS or trypsin and HA cleavage was 
detected by Western blot analysis of cell lysates. Arrows indicate the HA0 (upper arrow) and the HA1 
(lower arrow) subunits. Detection of β-actin served as loading control. Similar results were obtained 
in three independent experiments.  (B) The indicated proteases were expressed in 293T cells and the 
cells were infected with FLUAV A/PR/8/34 (H1N1) at an MOI of 0.01 or FLUAV 
A/Panama/2007/1999 (H3N2) at an MOI of 0.1 and either treated with trypsin or PBS. At 48 h post 
infection the number of infectious units into the culture supernatants was quantified employed a focus 
formation assay. The results of representative experiments performed with triplicate samples are 
shown. Error bars indicate standard deviations. Similar results were obtained in three independent 
experiments. ffu, focus forming units. 
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FIG 3 The 2-2-2-3 chimera cleaves and activates SARS-S and MERS-S. (A) In brief, 293T effector 
cells were transfected with either empty plasmid (pCAGGS) or pCAGGS encoding SARS-S. In parallel, 
293T target cells were transfected with empty plasmid (pCAGGS) or plasmids encoding ACE2 and the 
indicated proteases. Effector and target cells were mixed, treated with PBS or trypsin, and SARS-S 
cleavage was analyzed by Western blotting with a V5-specific antibody. The expression of β-actin 
served as a loading control. The results are representative of three independent experiments with 
different plasmid preparations. Black-filled arrowhead, uncleaved SARS-S; gray-filled arrowhead, S2 
subunit generated by trypsin digest; white-filled arrowheads, C-terminal cleavage fragments generated 
by TMPRSS2. (B) To analyze activation of SARS-S and MERS-S for virus-cell fusion, 293T cells 
were transiently transfected with plasmids encoding the indicated proteases and ACE2 or DPP4, 
respectively. At 24 h post transfection, the cells were pretreated with medium supplemented with 
DMSO or 10 µM cathepsin B/L inhibitor MDL 28170, and transduced with pseudotypes bearing 
SARS-S or MERS-S. The luciferase activities in cell lysates were analyzed at 72 h post transduction. 
The results of representative experiments performed with triplicate samples are shown. Error bars 
indicate standard deviations. Similar results were obtained in two separate experiments. c.p.s., counts 
per second. 
 
FIG 4 The TMPRSS2 stem region determines HA cleavage. (A) Schematic representation of the 
chimeric protease analyzed. (B) Plasmids encoding TMPRSS2, TMPRSS3 and chimera3-3-2-3 
equipped with an N-terminal myc tag were transfected into 293T cells. Empty plasmid (pCAGGS) 
served as a negative control. Protease expression in cell lysates was detected via Western blotting 
with anti-myc antibody.  The results of a representative experiment are shown and were confirmed in 
three separate experiments. Expression of β-actin served as a loading control. (C) 293T cells were 
cotransfected with plasmids encoding FLUAV HA of subtype H1 and chimera 3-3-2-3 or empty 
plasmid (pCAGGS) and then treated with PBS or trypsin. At 48 h post transfection the HA cleavage 
in the cell lysate was analyzed by Western blotting. Detection of β-actin served as loading control. 
Similar results were obtained in three independent experiments. (D) The indicated proteases were 
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transiently expressed in 293T cells and the cells were infected with FLUAV A/PR/8/34 (H1N1) at an 
MOI 0.01 (left) or FLUAV A/Panama/2007/1999 at an MOI of 0.1 (right) and treated with either 
trypsin or PBS. At 48 h post infection, the virus release was measured by determination of infectious 
particles in the culture supernatant. The results of representative experiments performed with triplicate 
samples are shown. Error bars indicate standard deviations. Similar results were obtained in three 
independent experiments. ffu, focus forming units. 
 
FIG 5 The stem region of TMPRSS4 determines HA cleavage and activation. (A) Schematic 
representation of the chimeric proteases analyzed. (B) 293T cells were transiently transfected with 
plasmids encoding the indicated proteases equipped with an N-terminal myc tag or with empty 
plasmid (pCAGGS) as negative control. Protease expression in cell lysates was detected via Western 
blotting with anti-myc antibody. The expression of β-actin served as a loading control. Similar results 
were obtained in three separate experiments.  (C) 293T cells were cotransfected with plasmids 
encoding the FLUAV HA of subtype H1 and the indicated proteases or empty plasmid (pCAGGS) 
and then treated with PBS or trypsin. At 48 h post transfection the HA cleavage in cell lysate was 
analyzed via Western blotting. Detection of β-actin served as loading control. Similar results were 
obtained in three independent experiments. (D) The indicated proteases were expressed in 293T cells 
and the cells were infected with FLUAV A/PR/8/34 (H1N1) at an MOI 0.01 and treated with either 
trypsin or PBS. At 48 h post infection, the number of infectious units present in culture supernatants 
was determined using the focus formation assay. The results of representative experiments performed 
with triplicate samples are shown. Error bars indicate standard deviations. Similar results were 
obtained in three independent experiments. (E) The experiment was performed as described for panel 
(D) but the cells were infected with FLUAV A/Panama/2007/1999 at an MOI of 0.1. (F) To analyze 
activation of MERS-S for virus-cell fusion, 293T cells were transfected with plasmids encoding the 
indicated proteases and DPP4. At 24 h post transfection, the cells were pretreated with medium 
supplemented with DMSO or 10 µM cathepsin B/L inhibitor MDL 28170 and transduced with MLV 
pseudotypes bearing MERS-S. At 72 h post transduction, the luciferase activities in cell lysates were 
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measured. The results of a representative experiment performed with triplicate samples are shown and 
were confirmed in three separate experiments. Error bars indicate standard deviations. ffu, focus 
forming units; c.p.s., counts per second. 
 
FIG 6 The stem region of TMPRSS2 determines colocalization with HA. (A) Plasmids encoding the 
indicated proteases were transfected into COS-7 cells. Subsequently, the cells were infected with 
FLUAV A/PR/8/34 (H1N1) at an MOI 0.5. At 24 h post infection, the cells were fixed with ice-cold 
methanol and stained for FLUAV-HA (green) and proteases (red). White squares show examples of 
colocalization of HA and proteases (yellow signals) which were digitally magnified by 4-fold. Similar 
results were obtained in three separate experiments. (B) The colocalization of proteases and HA was 
determined by analyzing images with Fiji software, which allows calculation of the Pearson 
Correlation Coefficient (PCC). The average PCC measured for 4-7 cells from separate experiments is 
shown, error bars indicate standard error of the mean (SEM). 
 
FIG 7 Dextran sulphate inhibits activation of FLUAV HA by TTSPs containing a SR-A domain. (A) 
Alignment of the protein sequences of the SR-A domain in the TMPRSS2 stem region and the SRCR 
of SR-A. Red, small and hydrophobic: blue, acidic; magenta, basic; green, hydroxyl and sulfhydryl 
and amine. *, full conservation; :, strong conservation; .,  weak conservation. (B) 293T cells were 
transfected with plasmids encoding indicated proteases and infected with FLUAV A/PR/8/34 (H1N1) 
at an MOI 0.01 and treated with either trypsin or PBS. After infection, the medium was replaced with 
fresh medium containing either PBS, 100 µg/ml dextran sulphate or 100 µg/ml chondroitin sulphate. 
At 48 h post infection, the infectious units present in culture supernatants were quantified. The 
infectious units measured in PBS treated cultures were set as 100%. The average of three independent 
experiments carried out with triplicate samples is shown, error bars indicate SEM. The numbers above 
the white bars indicate the fold increase in viral titers relative to pCAGGS transfected cells. (C) Caco-
2 (left) or Calu-3 (right) cells were infected with FLUAV A/PR/8/34 (H1N1) at an MOI 0.01 and 
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treated with increasing amount of dextran sulphate or chondroitin sulphate. The release of infectious 
units in culture supernatants was analyzed at 48 h post infection using a focus formation assay. The 
results of representative experiments performed with triplicate samples are shown. Error bars indicate 
standard deviations. (D) 293T cells were cotransfected with plasmid encoding FLUAV HA and the 
indicated proteases and treated with PBS, 100 µg/ml dextran sulphate or 100 µg/ml chondroitin 
sulphate. At 48 h post transfection, the HA cleavage was determined by Western blotting. Similar 
results were obtained in three independent experiments. The HA0 (upper arrow) are HA1 (lower 
arrow) subunits are indicated.  The expression of β-actin served as loading control. (E) Three Western 
blot experiments carried out as described for panel (D) were quantified using Fiji software. The 
pictures from three independent experiments were analyzed with Plot Lanes, and the sum of HA0 and 






Page | 71  
 
  
Page | 72  
 
  
Page | 73  
 
 
Page | 74  
 
  
Page | 75  
 
  
Page | 76  
 
 
Page | 77  
 
  




TMPRSS2 isoforms 1 activates respiratory viruses  
and is expressed in viral target cells 
Zmora. P., Moldenhauer, A.S., Pöhlmann, S. 













Design and conduct of the experiments. Bioinformatical analysis of TMPRSS2 isoforms (Fig. 
1A). Construction of the plasmid encoding TMPRSS2 isoform 1 and determination of 
TMPRSS2 isoforms expression in transiently transfected 293T cells (Fig. 1B). Analysis of 
the TMPRSS2 isoforms expression in different organs/cell lines via RT-PCE (Fig. 2). 
Microscopy analysis of TMPRSS2 isoforms and hemagglutinin localization (Fig. 3A) and 
statistical analysis of Person correlation coefficient (Fig. 3B). Western blot analysis of 
emerging coronaviruses S protein cleavage by TMPRSS2 isoforms (Fig. 5A) and 
determination whether TMPRSS2 isoform 1 activates the S-driven virus-cell fusion (Fig. 5B). 
Writing parts of the manuscript (Material and Methods, Results) 
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Tetherin sensitivity of influenza A viruses is strain specific:  
Role of hemagglutinin and neuraminidases  
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Gärtner, S., Moldenhauer, A.S., Hofmann-Winkler, H., Wolff, T.,  
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Analysis of the dose-dependence of the tetherin-mediated inhibition of the influenza virus 
release (Fig. 3A).  Demonstration that tetherin blocks influenza virus release from MDCK 
cells (Fig. 3C). Knock-down of tetherin expression in a lung-derived cell line by siRNA (Fig. 
4A) and analysis of its effects on influenza virus release  (Fig. 4B). Demonstration that 
pandemic but not seasonal influenza viruses downregulate of tetherin expression in a 
hemagglutinin/neuraminidase-dependent fashion (Fig. 6A) and quantification and statistical 
analysis of the results (Fig. 6B). Analysis whether influenza viruses preferentially infect 
tetherin-positive/negative cells (Fig. R1 in rebuttal letter). Showing that tetherin expression 
does not modulate the efficiency of influenza virus cell entry (Fig. R2 in rebuttal letter). 
Writing parts of the manuscript (Material and Methods, Results) 
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Analysis of tetherin expression in the presence of TTSPs via Western blotting (Fig. 2A). 
Determination whether tetherin-mediated inhibition can be counteracted by TTSPs  (Fig. 3A). 
Analysis of the effect of tetherin on the virus release (Fig. 6B). Analysis of the siRNA knock-
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ABSTRACT 
The host cell protein tetherin can inhibit the release of enveloped viruses from infected 
cells and constitutes an important defense against viral infection. Influenza viruses, 
major human pathogens, are largely resistant against tetherin’s antiviral activity but 
the mechanism underlying resistance is unclear. Here, we show that the cellular 
protease TMPRSS2, which activates the influenza virus hemagglutinin for host cell 
entry, also cleaves tetherin and facilitates viral release from tetherin-positive cells. 
TMPRSS2 was coexpressed with tetherin in bronchial epithelium, a target of influenza 
virus infection, suggesting that TMPRSS2 might promote viral release in the infected 
host. These results indicate that influenza viruses exploit TMPRSS2 to ensure two 
important functions in viral replication, hemagglutinin activation and viral release from 
infected cells. The unexpected finding that a virus-activating host cell factor can counter 
an innate antiviral defense mechanism may have important implications for 
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IMPORTANCE 
Host cell encoded antiviral effector proteins can inhibit virus invasion and are 
important components of innate immune defenses. Understanding how viruses evade 
the antiviral activity of these effector proteins might afford novel approaches to 
antiviral therapy and is thus in the focus of current research efforts. It has been 
established that several viruses encode proteins, which antagonize antiviral effectors, 
for instance by reducing their expression. Here, we report for the first time that an 
antiviral effector, tetherin, can be inhibited by another host cell encoded protein, the 
protease TMPRSS2. These results suggest that the cellular environment can determine 
whether an antiviral effector protein can unfold its full activity and help to define 
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INTRODUCTION 
Mammalian cells are equipped with antiviral effector proteins, which target specific 
components of invading viruses and restrict viral spread (1, 2). Expression of these virus-
restricting factors (restriction factors) is frequently inducible by interferons (IFNs) and their 
activity is integral to the control of viral spread by the IFN system (1). As a consequence, 
viruses evolved countermeasures which antagonize restriction factors and allow efficient viral 
spread despite activation of the IFN system (1, 2). The host cell protein tetherin (BST-2, 
CD317) is an IFN-inducible restriction factor, which targets the viral envelope and inhibits 
release of progeny particles from infected cells (3). The antiviral activity of tetherin has 
initially been identified in the context of HIV-1 infection and the HIV-1 accessory protein 
Vpu was found to counteract tetherin (4, 5). Recent studies conducted in mice indicate that 
tetherin’s potent anti-retroviral activity displayed in cell culture translates into robust 
inhibition of viral spread in the host (6-9), indicating that tetherin is an important component 
of the innate defenses against retroviral infection.  
Tetherin exhibits a particular domain organization and membrane topology which is 
key to its antiviral activity (3, 10). It contains an N-terminal cytoplasmic domain, followed by 
a membrane spanning domain, an extracellular coiled-coil domain and a C-terminal 
glycosylphosphatidylinositol (GPI)-anchor (11). The presence of two membrane anchors 
allows the protein to simultaneously insert into the viral and the host cell membrane. As a 
consequence, tetherin can form a physical tether between progeny virions and the plasma 
membrane of the host cell, which prevents release of infectious viral particles into the 
extracellular space (4, 12-15). The integral role of tetherin’s topology in its antiviral action is 
underlined by the observation that an engineered protein, which does not share sequence 
homology with tetherin but exhibits a comparable domain organization, can also suppress 
viral release (12). 
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The finding that tetherin targets the viral membrane and prevents release of virions 
from the plasma membrane suggests that most if not all enveloped viruses which exit host 
cells via the plasma membrane and do not encode a tetherin antagonist should be inhibited by 
tetherin. Indeed, evidence has been provided that - in the absence of viral countermeasures - 
tetherin is active against many viruses belonging to diverse families, including retroviridae 
(4, 14-20), paramyxoviridae (21, 22), filoviridae (23-26), herpesviridae (27), flaviviridae (28, 
29), togaviridae (30)  and arenaviridae (22, 25, 31). Influenza viruses, members of the family 
orthomyxoviridae, constitute a notable exception: Although these viruses are released from 
the plasma membrane (32, 33), ambiguous results were reported concerning their sensitivity 
towards tetherin. Thus, three studies did not detect appreciable inhibition of influenza A virus 
(FLUAV) release by tetherin (34-36). The same number of reports indicated that release of 
FLUAV is blocked by tetherin but the inhibition efficiency was lower than that commonly 
observed for vpu-defective HIV-1 (37-39). Notably, tetherin inhibited release of FLUAV-like 
particles (fVLPs) but not authentic FLUAV (35, 40), suggesting that viral proteins lacking in 
fVLP-producing cells but present in FLUAV infected cells might function as tetherin 
antagonists. Indeed, variants of the viral neuraminidase (NA) with an aspartate at position 
286 (N2)/268 (N1) were shown to be budding competent (40), to inhibit tetherin’s antiviral 
activity in cell culture (38), potentially by modifying tetherin glycosylation (37), and to be 
associated with increased viral replication in mice (38), although the effects observed were 
generally modest. In addition, we recently reported that the HA proteins of pandemic but not 
seasonal or lab-adapted FLUAV can antagonize tetherin (41). Thus, FLUAV seems to encode 
tetherin antagonists but it is unlikely that they account for the full spectrum of tetherin 
resistance observed within previous studies. 
Here, we addressed the possibility that host cell proteins present in FLUAV target 
cells might render the virus insensitive to inhibition by tetherin. We focused our study on host 
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cell proteases, since activation of the FLUAV hemagglutinin (HA) by cellular proteases is 
essential for viral infectivity (42) and purified trypsin (which is commonly used to activate 
influenza viruses in protease-negative cells) or related proteases are known to abrogate 
tetherin’s antiviral activity (13, 15, 43). Specifically, we asked whether the type II 
transmembrane serine proteases (TTSPs) TMPRSS2, TMPRSS4 and HAT, DESC1 and 
MSPL, which activate HA in cell culture (44-46), also counteract tetherin. Particular focus 
was placed on TMPRSS2, since expression of this protease is essential for FLUAV spread in 
mice (47-49). We found that exogenous and endogenous expression of these proteins results 
in tetherin cleavage and inactivation of tetherin’s antiviral function. Moreover, we 
demonstrate that TMPRSS2 and tetherin are coexpressed in the human lung. These 
observations indicate that FLUAV evades tetherin’s antiviral activity by targeting cells which 
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MATERIAL AND METHODS 
 
Cell culture and plasmids. 293T cells were cultured in Dulbecco’s modified Eagle medium 
(DMEM, Invitrogen) while Caco-2 cells were cultured in DMEM GlutaMax (Invitrogen). All 
media were supplemented with penicillin, streptomycin and 10% fetal bovine serum. Cells 
were culture in a humidified atmosphere containing 5% CO2. The plasmids encoding HIV-1 
NL4-3 wt and ∆vpu proviral DNA (50), proteases (46, 51-53), NA of the 1918 FLUAV (45), 
genomic segments of A/Panama/2007/99 (H3N2) (54), tetherin and viral tetherin antagonists 
(26) were described previously. Splice overlap extension PCR was employed to delete amino 
acids 21-48 in tetherin, which comprise the complete transmembrane domain, resulting in 
construct tetherin ΔTM. The plasmids pECFP and pEYFP, pECFP-EYFP, pEYFP-Vpu and 
pECFP-MEM have already been described (55). TMPRSS2 and TMPRSS6 N-terminally 
fused to YFP were generated by PCR amplification of the protease coding sequence followed 
by insertion into plasmid pEYFP-C1 (Clontech). The integrity of all PCR-amplified 
sequences was verified by automated sequencing. 
 
Analysis of tetherin expression. For analysis of tetherin expression in cell lysates, 293T 
cells coexpressing tetherin and viral tetherin antagonists or TTSPs were washed with PBS 
and lysed with SDS-loading buffer (50 mM Tris pH 6.8, 10% glycerol, 2% SDS, 5% β-
mercaptoethanol, 0.1% bromphenolblue, 1 mM EDTA). Subsequently, samples were 
incubated for 30 min at 95°C and separated by SDS-PAGE. Proteins were transferred onto 
nitrocellulose membranes and detected employing rabbit anti-tetherin antisera ((56), Abcam) 
and horseradish-peroxidase-coupled anti-rabbit antibody (Dianova) or mouse monoclonal 
anti-tetherin antibody (eBIOSCIENCE) jointly with horseradish-peroxidase-coupled anti-
mouse antibody (Dianova). Staining was visualized with ECL Prime Western Blotting 
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Detection Reagent (Amersham) following the manufacturer’s protocol. For analysis of 
tetherin expression at the cell surface, 293T cells coexpressing tetherin and viral tetherin 
antagonists or TTSPs were mechanically detached, washed with FACS buffer (PBS with 
0.5% FCS) and stained with anti-tetherin monoclonal antibody (eBIOSCIENCE). Mouse 
IgG1κ (R&D Systems) was employed as isotype-matched control. After 30 min of incubation 
with primary antibodies at 4°C, cells were washed twice with FACS buffer and incubated for 
30 min at 4°C with DyLight 647-coupled anti-mouse secondary antibodies (Dianova). After 
two final washing steps, cells were fixed with 2% paraformaldehyde and analyzed with a BD 
LSR II flow cytometer. 
 
Analysis of tetherin antagonism employing lentiviral particles. To analyze inhibition of 
viral release by tetherin and its counteraction, a previously published VLP system was 
employed (26). In brief, 293T cells were seeded at a density of 2.6 x 10
5
 cells/well in 6-well 
plates and calcium phosphate-cotransfected with plasmids encoding Gag, tetherin and either 
Vpu, EBOV-GP or TTSPs at a ratio of 2:1:1 (total amount of 6 µg plasmid/well). As control, 
cells were cotransfected with empty plasmid. At 48 h after transfection, supernatants were 
collected and cleared by centrifugation at 3,500 g for 8 min. Subsequently, supernatants were 
loaded on top of 20% sucrose in TNE buffer and centrifuged at 21,100 g for at least 2 h at 
4°C. Thereafter, supernatants were removed and concentrated VLPs were mixed with 30 µl 
SDS-loading buffer. For production of cell lysates, the cells were washed with PBS and 
detached with 200 µl/well SDS-loading buffer. For some experiments, concentrated VLPs 
and cell pellets were treated with PNGaseF for 1 hour at 37°C as described by the 
manufacturer’s protocol (New England Biolabs). All samples were denatured for 30 min at 
95°C, separated by SDS-PAGE and proteins detected by Western blot, employing the anti-
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p24 hybridoma cell culture supernatant (183-H12-5C) for detection of Gag (57) and anti-
CD317 monoclonal antibody (eBIOSCIENCE) for detection of tetherin fragments.  
 
siRNA knock-down and particle release from Caco-2 cells. Caco-2 cells were seeded in 6-
well plates at 3 × 10
5
 cells/well. After 24 h, the culture medium was replaced by Opti-MEM 
medium (Invitrogen) and the cells were cotransfected with 200 pmol scrambled siRNA or 
siRNAs specific for tetherin or TMPRSS2 (Santa Cruz) jointly with 4 µg expression plasmids 
encoding for HIV-1 NL4-3 wt or HIV-1 NL4-3 ∆vpu, employing Lipofectamin 2000 as 
recommended by the manufacturer (Invitrogen). Alternatively, cells were cotransfected with 
siRNAs and influenza virus NA expression plasmid. Supernatants and cell lysates were 
harvested at 48 h post transfection and analyzed as described above for VLP-producing cells. 
Expression of NA was analyzed employing an anti-V5-specific antibody (Invitrogen). 
 
Influenza A viruses. A/PR/8/34 (H1N1) and A/Panama/2007/99 (H3N2) were propagated in 
the chorio-allantoic cavity of 10-day-old embryonated hen eggs (Harlan Winkelman, 
Germany) for 48 h at 37°C. A/Panama/2007/99 (H3N2) was reconstituted from an 8-plasmid 
system (54) before amplification in eggs. 
 
Tetherin antagonism of influenza A virus release. 293T cells were seeded in 6-well plates 
at a density of 2.8 × 10
5
 cells/well. After 24 h, the cells were transfected with 6 µg expression 
plasmids encoding for tetherin, TMPRSS2 or a catalytically inactive TMPRSS2 mutant using 
the calcium phosphate transfection method. The transfection medium was replaced by fresh 
medium after an overnight incubation. At 24 h post transfection the culture medium was 
removed and the cells were infected with A/PR/8/34 (H1N1) at an MOI of 0.1 and with 
A/Panama/2007/99 (H3N2) at an MOI of 0.3. For this, culture medium was removed and 
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) supplemented with 0.2% BSA was added. 
After 1 h, the infection medium was removed, the cells were gently washed and DMEM 
supplemented with 0.2% BSA was added. Culture supernatants were collected after either 8 
or 24 h post infection. The amount of infectious units within the culture supernatants was 
determined by focus formation assay. Alternatively, Caco-2 cells were seeded in 12-well 
plates at a density of 1.4 x 10
5 
cells/well and transfected with 1 µg of siRNA specific for 
tetherin or TMPRSS2 or scrambled, non-sense siRNA as described above. At 24 h post 
transfection, the cells were infected with A/PR/8/34 (H1N1) at an MOI 0.01, as described 
above. The supernatant was collected at 24 h post infection, and the virus titers were 
determined using focus formation assay. 
 
Focus formation assay. Virus titers were determined on MDCK II cells using the focus 
formation (FOCI) assay as described (36, 58). Briefly, MDCK II cells were seeded in 96-well 
culture plates at a density of 4-6 x 10
4
 cells/well and serial 2-, 5- or 10-fold dilutions of 
culture supernatants prepared in DMEM containing 2.5 μg/ml NAT (N-Acetylated Trypsin, 
Sigma), 0.1% BSA, 1% penicillin/streptomycin were added. After 1 h of incubation, 
inoculates were replaced with 100 μl of 1% Avicel overlay medium and the cells were 
incubated for 24 h. Subsequently, the cells were washed twice with PBS and fixed with 4% 
formalin in PBS for 10 min at room temperature. Then, cells were washed twice and 
incubated with quencher (100 μl/well; 0.5% Triton X-100, 20 mM Glycine in PBS) for 
10 min at room temperature. Thereafter, cells were washed with washing buffer (100 μl/well; 
0.5% Tween20 in PBS) and blocked with blocking buffer (50 μl/well; 0.5% Tween, 20% 
BSA in PBS) for 30 min at 37 °C in 5% CO2. Subsequently, primary antibody (anti-influenza 
NP polyclonal goat antibody, Virostat, or anti-FLUAV (H1N1), Millipore) was added and the 
cells incubated for 1 h. Finally, the cells were washed and incubated with secondary antibody 
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(anti-goat-HRP, Dianova)  for 1 h in the dark, then washed again and incubated with 
substrate (True Blue from KPL, MA, USA) and exposed until blue spots from infected cells 
appeared. Foci were counted and viral titers were calculated as focus formation units (FFU) 
per ml of culture supernatant.  
 
Confocal microscopy and FACS-based FRET assay. For the analysis of the subcellular 
localization of tetherin, TMPRSS2 and TMPRSS6, transfected 293T cells seeded on cover 
slips were calcium phosphate transfected to express the respective CFP and YFP-labeled 
fusion proteins. After 24 h, cover slips were mounted on objective slides with Mowiol 
containing DRAQ5 (1 µg/ml) to visualize DNA. Areas of fluorescent protein expression were 
visualized by confocal spinning disc microscopy at 63 x magnification with an oil immersion 
objective (Nikon TiE equipped with the PerkinElmer UltraView Vox system). FACS-based 
FRET was performed and quantified essentially as described before (55, 59). Briefly, 293T 
cells were seeded in 12-well plates at 1.5 x 10
5
 cells/well and calcium phosphate transfected 
with 1.25 µg of each CFP/YFP expression plasmid. At 6 h post transfection medium was 
changed and at 24 h post transfection cells were harvested for FACS-FRET analysis with a 
FACSCantoII (BD). CFP/YFP double positive cells were gated first and subsequently the 
FRET background signal was defined according to the pECFP and pEYFP cotransfected 
negative control. At least 3,000 double positive cells were analyzed for every transfection. 
For data evaluation, the percentage of cells exerting higher FRET fluorescence than the 
negative control was quantified. Filter settings were CFP (ex 405 / em 450), YFP (ex 488 / 
em 525) and FRET (ex 405 / em 525).    
 
Immunohistochemistry. For in vivo examination of tetherin distribution in human airway 
epithelium, primary bronchi segments were fixed and immunostained as previously described 
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(60). Mouse monoclonal anti-TMPRSS2 (Santa Cruz) and rabbit polyclonal anti-tetherin 
were applied as primary antibodies. Donkey derived, Dylight 488 labeled, anti-mouse IgG 
(H+L) and Dylight 647 labeled anti-rabbit IgG (H+L) were applied as secondary antibodies. 
Thereafter, the cells were incubated with Cy3-conjugated mouse anti-β-tubulin (Tub2.1; 
Sigma Aldrich) for staining of ciliated cells and counterstained with DAPI (Invitrogen). 
Fluorescent images were acquired using EC Plan Neo-fluar 40x/1.30 Oil DIC M27 objective 
on a Zeiss LSM 710 confocal microscope. Image capture, analysis and processing were 




















FLUAV activating type II transmembrane serine proteases antagonize tetherin. We first 
investigated whether coexpression of TTSPs interferes with tetherin-mediated restriction of 
viral release. For this, we employed a well-established HIV-1 Gag-based VLP system or 
authentic HIV-1, since this experimental approach allows to measure anti-tetherin activity of 
TTSPs in the absence of confounding effects resulting from virus activation by these 
proteases (TTSPs activate FLUAV but not HIV-1). Coexpression of TTSPs did not impact 
expression of HIV-1 Gag in cell lysates or release of Gag from tetherin-negative cells (Fig. 
1A). Similarly, no effect of Vpu and the Ebola virus glycoprotein (EBOV-GP), a tetherin 
antagonist (24), on Gag expression and release from tetherin-negative cells was seen. Release 
of Gag was markedly diminished upon coexpression of tetherin and this effect was largely 
rescued upon coexpression of Vpu or EBOV-GP (Fig. 1a), as expected (4, 24). Notably, 
expression of the FLUAV-activating TTSPs, TMPRSS2, TMPRSS4 and HAT, also 
abrogated inhibition of VLP release by tetherin, while no rescue was observed upon 
coexpression of TMPRSS3 and TMPRSS6 (Fig. 1A), which fail to activate FLUAV (42). 
Analysis of a catalytically inactive mutant of TMPRSS2 revealed that tetherin antagonism 
was dependent on the protease activity (Fig. 1B) and the robust and comparable expression of 
epitope-tagged proteases in the transfected cells (Fig. 1C) revealed that lack of anti-tetherin 
activity of TMPRSS3 and TMPRSS6 was not due to insufficient expression. Thus, the 
FLUAV-activating proteases TMPRSS2, TMPRSS4 and HAT can apparently antagonize the 
antiviral activity of tetherin. 
 
FLUAV activating type II transmembrane serine proteases differentially interfere with 
tetherin expression. Tetherin antagonism by TTSPs might result from interference with 
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appropriate tetherin expression in cells and at the cell surface, as previously demonstrated for 
HIV-1 Vpu (4). Coexpression of Vpu indeed reduced total tetherin expression and cell 
surface levels (Fig. 2A,B), as expected (4). In contrast, tetherin levels were not modulated by 
coexpression of EBOV-GP (Fig. 2A,B), again in agreement with published work (26, 61). 
Similarly, tetherin expression remained largely unchanged upon coexpression of most TTSPs. 
The only exception was observed upon TMPRSS4 expression, which markedly reduced 
intracellular levels of tetherin (Fig. 2A) but, for at present unclear reasons, had little if any 
impact on cell surface levels of tetherin (Fig. 2B). Similarly, expression of the other TTSPs 
analyzed had no significant effects on surface expression. These observations indicate that 
TMPRSS2 and HAT antagonize tetherin without appreciably modulating tetherin expression 
while TMPRSS4 robustly reduces total tetherin expression. 
 
FLUAV activating type II transmembrane serine proteases cleave tetherin. The finding 
that some TTSPs can antagonize tetherin without interfering with tetherin expression 
prompted us to investigate whether TTSPs facilitate tetherin proteolysis, which can 
compromise tetherin’s antiviral activity (13, 15, 43). To address this question, we examined 
whether tetherin fragments are present in supernatants of cells coexpressing TTSPs and Gag. 
For this endeavor, we extended our TTSP panel to hepsin, DESC1 and MSPL, which can 
cleave HA (46), and to TMPRSS1B, TMPRSS11F, prostasin, TMPRSS9 and TMPRSS10, 
which are unable to process HA despite robust expression in 293T cells (46). All TTSPs 
known to cleave and activate HA liberated Gag release from inhibition by tetherin and robust 
tetherin signals of approximately 20 kDa were readily observed in the supernatants of cells 
coexpressing TMPRSS2, MSPL and hepsin (Fig. 3A). In addition, tetherin fragments were 
also observed upon coexpression of TMPRSS4 and HAT in some experiments (not shown). 
In contrast, proteases unable to activate HA consistently failed to antagonize tetherin and to 
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facilitate release of tetherin fragments into the extracellular space (Fig. 3A). Similarly, 
coexpression of EBOV-GP and Vpu did not result in efficient release of tetherin fragments. 
Moreover, in some but not all experiments coexpression of TMPRSS2, hepsin and MSPL 
resulted in the accumulation of a tetherin form in cell lysates which displayed the same 
molecular weight as the tetherin fragment observed in supernatants (Fig. 3A). Collectively, 
these findings suggested that TTSPs might cleave and thereby antagonize tetherin.   
We next sought to provide direct proof for tetherin cleavage. For this, we focused on 
experiments in which faint tetherin signals were detected in supernatants of control cells and 
EBOV-GP expressing cells, potentially due to particularly high transfection efficiency. 
PNGase F digest, which removes all N-linked glycans, showed that the diffuse tetherin 
signals in these supernatants were due to heterogenous glycosylation of tetherin (Fig. 3B). 
More importantly, removal of N-glycans revealed the presence of an approximately 14 kDa 
tetherin fragment in supernatants from cells coexpressing TMPRSS2 but not EBOV-GP or 
empty plasmid (Fig. 3B), indicating that TMPRSS2 indeed cleaves tetherin.  Thus, our 
observations are consistent with a model, in which tetherin cleavage by TTSPs, in analogy to 
tetherin proteolysis by trypsin, mediates the release of otherwise surface-tethered virions into 
the extracellular space.   
 
TMPRSS2 and tetherin colocalize. The ability of HA-activating TTSPs to cleave tetherin 
suggests that TTSPs and tetherin might colocalize. Confocal microscopy of cells 
coexpressing tetherin and TTSPs fused to fluorescent proteins indeed revealed extensive 
colocalization of tetherin and TMPRSS2 at the plasma membrane and within cytoplasmic 
compartments (Fig. 4A) In contrast, colocalization of tetherin and TMPRSS6 was much less 
robust (Fig. 4A). Similar results were obtained when the potential interaction of these 
proteins was studied employing a previously described FACS-based FRET assay (55), for 
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which expression of CFP and YFP alone served as negative control while CFP fused to YFP 
served as positive control (Fig. 4B). In this assay, a robust FRET signal was measured upon 
coexpression of Vpu and tetherin, as expected (55), and upon coexpression of tetherin and 
TMPRSS2 (Fig. 4B). In contrast, FRET in tetherin and TMPRSS6 transfected cells was much 
lower and no appreciable signal was detected when the proteases were coexpressed with the 
fluorescent proteins fused to a membrane targeting signal (Fig. 4B). Thus, TMPRSS2, like 
Vpu, is in the same subcellular compartment and directly interacts with tetherin. 
 
Endogenous TMPRSS2 promotes release of retroviral particles from Caco-2 cells. Our 
analysis so far showed tetherin counteraction by TTSPs in transfected cells. In order to 
examine if tetherin antagonism is also operative upon endogenous expression of protease and 
tetherin, we analyzed release of wt and vpu-defective HIV-1 from the colon carcinoma cell 
line Caco-2. Caco-2 cells were chosen for our analysis because these cells express 
endogenous tetherin (Fig. 5) and TMPRSS2 and support influenza virus spread in a trypsin-
independent, TMPRSS2-dependent manner (51, 62). Transfection of Caco-2 cells with 
tetherin-specific siRNA resulted in a marked knock-down of tetherin expression (Fig. 5). 
Lack of efficient detection of TMPRSS2 expression by Western blot precluded a similar 
analysis for TMPRSS2-specific siRNA. However, TMPRSS2 transcripts are abundant in 
Caco-2 cells (51, 63) and our previous study conducted with a different batch of Caco-2 cells 
clearly demonstrated that the siRNA employed here effectively and specifically reduces 
TMPRSS2 expression in this cell line (51). Knock-down of tetherin expression in cells 
containing HIV-1 proviral DNA slightly increased release of wt HIV-1 while knock-down of 
TMPRSS2 expression modestly reduced viral release (Fig. 5), in keeping with tetherin 
antagonism by this protease. More strikingly, release of vpu-negative HIV-1 was markedly 
enhanced upon knock-down of tetherin but completely inhibited upon reduction of 
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TMPRSS2 expression (Fig. 5), consistent with the concept that TMPRSS2 promotes viral 
release by negatively regulating tetherin’s antiviral activity. 
 
TMPRSS2 promotes release of authentic influenza A viruses from tetherin expressing 
cells. Our analysis was so far based on the use of HIV-1 VLPs. This system is frequently 
employed to study tetherin but might not faithfully reflect FLUAV inhibition by tetherin. 
Therefore, we next investigated whether tetherin inhibits release of FLUAV-like particles and 
infectious FLUAV and whether this inhibition can be counteracted by TMPRSS2. 
Transfection of the NA of the 1918 FLUAV into Caco-2 cells resulted in the robust release of 
NA into the supernatant (Fig. 6A), in agreement with previous findings that NA triggers 
release of VLPs (40, 64). Release of NA-based VLPs was increased upon siRNA-mediated 
down-regulation of tetherin expression while knock-down of TMPRSS2 expression reduced 
viral release (Fig. 6A). These results mirror our observations made with retroviral VLPs and 
suggest that TMPRSS2 might promote FLUAV release from tetherin positive target cells. In 
order to investigate this, we analyzed viral release from cells transfected to express tetherin or 
control transfected with empty plasmid, employing a single-cycle of infection assay. We 
found that tetherin expression reduced the release of A/PR/8/34 (H1N1) and 
A/Panama/2007/99 (H3N2) strains by roughly 10-fold (Fig. 6B) and this effect was not 
observed when a tetherin mutant with deleted transmembrane domain was used (Fig. 6C). 
Notably, inhibition of viral release by tetherin was fully rescued upon coexpression of 
TMPRSS2 while expression of TMPRSS2 alone did not impact viral release (Fig. 6D). For 
this experiment, supernatants were collected at 8 h (Fig. 6D) instead of 24 h (Fig. 6B,C) post 
infection, in order to avoid multiple-rounds of infection supported by TMPRSS2-mediated 
HA activation. As a consequence, less infectious units were present in the supernatants 
assayed in figure 6D as compared to previously analyzed supernatants (Fig. 6B,C). However, 
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supernatants taken at 1 h post infection generally did not contain infectivity (not shown), 
indicating that the infectious units detected at 8 h time point were due to release of progeny 
virions. Finally, siRNA knock-down of endogenous tetherin in Caco-2 cells subtly increased 
viral release in a single-cycle assay (not shown) but markedly augmented multi-cycle 
FLUAV spread while knock-down of TMPRSS2 had the opposite effects (Fig. 6E). Thus, 
TMPRSS2 might counteract tetherin in cells endogenously expressing these proteins, 
although reduced viral spread upon TMPRSS2 knock-down might be partially due to 
diminished HA activation.  Collectively, these results suggest that exogenous and likely also 
endogenous TMPRSS2 can rescue FLUAV from inhibition by tetherin. 
 
TMPRSS2 and tetherin are coexpressed in human bronchial epithelium. A tetherin 
antagonizing activity of TMPRSS2 in the context of the infected host requires coexpression 
of protease and tetherin in viral target cells. Human bronchial epithelial cells express 
TMPRSS2 and the major receptor determinant for human influenza viruses, 2,6-linked sialic 
acid (52), and are permissive to influenza virus spread. Therefore, we analyzed if TMPRSS2 
and tetherin are coexpressed in the human bronchus. Immunofluorescence analysis of 
antibody-stained bronchial tissue demonstrated that bronchial epithelial cells, identified by 
their location in the analyzed tissue and by the prominent expression of β-tubulin, coexpress 
robust levels of tetherin and TMPRSS2 (Fig. 7). Thus, TMPRSS2 and tetherin are 
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DISCUSSION 
Understanding how tetherin exerts antiviral activity and how viruses evade inhibition by 
tetherin might allow for novel approaches to antiviral intervention and has been in the focus 
of recent research. The paradigm that enveloped viruses which bud from the cell surface are 
either inhibited by tetherin or encode a robust tetherin antagonizing activity has been verified 
for viruses from diverse families (4, 17-19, 24, 65, 66). For unclear reasons, FLUAV 
constitutes an exception to this rule (34-40). Our results indicate that FLUAV can acquire 
tetherin resistance by targeting cells which express tetherin antagonizing, HA-activating 
proteases. To our knowledge this is the first report of a cellular tetherin antagonist which can 
be exploited by viruses for efficient release from tetherin-positive cells. 
The influenza virus HA mediates viral entry into target cells. Activation of HA by 
host cell proteases is essential for viral infectivity but the enzymes which facilitate this 
process in the infected host have long been unclear (42). Recent analyses indicate a key role 
of TTSPs: In transfected cells TMPRSS2 and HAT activate the HA-proteins of all FLUAV 
subtypes previously pandemic in humans (44), endogenous TMPRSS2 activates influenza 
viruses for spread in Calu-3 (67) and Caco-2 cells (51) and TMPRSS2 and HAT are 
expressed in viral target cells in the aerodigestive tract (52). Moreover, a pioneer study by 
Hatesuer and colleagues demonstrated that TMPRSS2 expression is essential for spread and 
pathogenesis of H1N1 viruses in mice (47) and these results were confirmed by subsequent 
work (48, 49). Similarly, polymorphisms in TMPRSS2 which increase expression of this 
protease were shown to be associated with severe influenza in humans (68). In addition, 
hepatitis C virus (69), human metapneumovirus (70), respiratory parainfluenzaviruses (71) 
and several respiratory coronaviruses, including the highly pathogenic severe acute 
respiratory syndrome (72-75) and Middle East respiratory syndrome coronaviruses (71, 76), 
are activated by TMPRSS2 and might exploit this protease to ensure their spread in the 
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infected host. Our present results suggest that adaption to usage of TMPRSS2 and other 
TTSPs for activation of the viral surface protein might be associated with an additional 
benefit - protection from the antiviral action of tetherin. 
How do TTSPs antagonize tetherin? Our observations indicate that TTSPs could sever 
the tether between viral and host cell membrane, which impedes release of progeny virions 
from tetherin-positive cells. Such a mechanism would fit with the documented ability of 
trypsin to cleave and antagonize tetherin (13, 15, 43). In fact, TTSPs display a trypsin-like 
specificity and it is conceivable that both proteases cleave tetherin at identical sites. TTSPs 
are autocatalytically activated during transport to or upon insertion into the plasma membrane 
(77) and it is likely that these proteases cleave tetherin at the cell surface. Processing of 
tetherin by TMPRSS4 might be an exception. The profound depletion of total tetherin levels 
by this protease suggests that TMPRSS4 can also cleave tetherin during transport in the 
constitutive secretory pathway and thereby largely depletes intracellular tetherin pools. 
However, depletion is not complete since TMPRSS4 expression does not affect surface 
tetherin levels. In sum, tetherin joins influenza HA and coronavirus spike proteins as a TTSP 
substrate and tetherin cleavage is most likely responsible for tetherin counteraction by 
TTSPs. 
The demonstration that tetherin can robustly inhibit release of authentic, laboratory 
adapted and seasonal FLUAV is in agreement with work by some laboratories (37, 38) but 
does not match findings of three other studies, including our own work, demonstrating that 
tetherin has at best a modest effect on FLUAV release (34-36). One explanation for these 
discrepant results could be that the cells used for these studies differed in tetherin expression 
levels. A second parameter which could impact FLUAV inhibition by tetherin is the presence 
of trypsin, which activates FLUAV but inactivates tetherin (13, 15, 43). To avoid such a 
potentially confounding effect, we analyzed the antiviral activity of tetherin in the absence of 
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trypsin. In addition, FLUAV infection experiments involving coexpression of TMPRSS2 and 
tetherin were terminated at 8 h post infection (except for figure 6e), in order to ensure that 
rescue of FLUAV from inhibition by tetherin was due to tetherin inactivation by TMPRSS2 
and not to augmented viral spread as a consequence of HA activation by this protease. In 
sum, tetherin can inhibit FLUAV release and this inhibition is abrogated byTMPRSS2. 
Is tetherin able to inhibit FLUAV in the infected host and is this inhibition rescued by 
TMPRSS2? Our analysis of TMPRSS2 and tetherin expression in human bronchial 
epithelium suggests that both might be the case. The expression of tetherin in epithelial cells 
of the human bronchus is in agreement with a previous study demonstrating constitutive 
expression of tetherin in many organs, including lung (78). TMPRSS2 is known to be 
coexpressed with 2,6-linked sialic acid throughout the respiratory tract (52) and the present 
finding that TMPRSS2 and tetherin are coexpressed in bronchial epithelium demonstrates 
that TTSPs could promote influenza virus spread in tetherin-positive pulmonary target cells – 
a scenario in keeping with the observation that tetherin knock-out does not augment spread of 
FLUBV in mice (79). Importantly, the biological relevance of tetherin antagonism by TTSPs 
might extend beyond the spread and pathogenesis of respiratory viruses which target TTSP-
positive cells. For one, the catalytic domain of several TTSPs is shed into the extracellular 
space (77, 80) and might inactivate tetherin on adjacent cells. Moreover, tetherin-inactivating 
TTSPs are expressed in extrapulmonary tissues and might determine whether viruses 
targeting these tissues are exposed to tetherin’s antiviral activity (77). Thus, TMPRSS2 
expression in lymphocytes (52) might impact release of HIV and SIV from these cells and 
evidence was obtained that TMPRSS2 in hepatocytes can activate HCV for host cell entry. 
Finally, inflammatory conditions can increase the activation of certain TTSPs (81)  and can 
induce the expression of other proteases (82), which might counter tetherin. 
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 Inhibition of virus activating cellular proteases is a promising approach to antiviral 
therapy and enzymes like TMPRSS2, which is important for viral spread (47, 48, 83) but 
dispensable for cellular survival (84) are important targets. Our study suggests that inhibitors 
like the IFN-induced serine protease inhibitor PAI-1, which targets TMPRSS2 and related 
proteases (39), might exert antiviral activity via two mechanisms: Inhibition of viral 
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FIG 1 Type II transmembrane serine proteases antagonize tetherin. (A) 293T cells were 
cotransfected with HIV-1 p55-Gag plasmid, tetherin plasmid (right panel) or empty plasmid 
(left panel), and plasmids encoding either Vpu, EBOV-GP, the indicated protease or no 
protein (control). Expression of p55-Gag and β-actin in cell lysates and the release of p55-
Gag in culture supernatants were analyzed by Western blot. Each panel shows the result of a 
single Western blot from which irrelevant lanes were removed. Similar results were obtained 
in five separate experiments.  (B) The experiment was carried out as described for (a) but 
catalytically inactive mutant of TMPRSS2 (TMPSS2 mut) was analyzed. The results were 
confirmed in two separate experiments. (C) To compare protease expression, 293T cells were 
transfected with plasmids encoding the indicated proteases equipped with a myc tag. Empty 
plasmid was used negative control (control) while a plasmid encoding myc-tagged EBOV 
VP40 was employed as positive control. Protein expression in cell lysates was detected by 
Western blot using anti-myc antibody. Detection of β-actin served as loading control. Similar 
results were obtained in two separate experiments. White filled arrowheads indicate zymogen 
forms while grey filled arrowheads highlight fragments generated upon activation and 
exhibiting a molecular weight expected for the protease domain. VLP, virus-like particle; 
TTSP, type II transmembrane serine protease; Sups, supernatants. 
 
FIG 2 Interference of type II transmembrane serine proteases with tetherin expression. (A) 
293T cells were cotransfected with a plasmid encoding tetherin and plasmids encoding the 
indicated TTSPs, Vpu or EBOV-GP or a plasmid encoding no protein (control). Expression 
of tetherin and β-actin in cell lysates was detected by Western blot. Similar results were 
obtained in three separate experiments. (B) The experiment was conducted as described for 
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(A) but tetherin expression was detected by FACS. The average of two to five independent 
experiments is shown. Error bars indicate standard error of the mean (SEM). Tetherin 
expression on cells cotransfected with empty plasmid (control) and tetherin encoding plasmid 
was set as 100%. Statistical significance was calculated using two-tailed students t-test. 
 
FIG 3 Type II transmembrane serine proteases cleave tetherin. (A) 293T cells were 
transfected with plasmids encoding HIV-1 p55-Gag, tetherin and either EBOV-GP, Vpu or 
the indicated proteases or encoding no protein (control). Cells transfected with empty plasmid 
alone served as negative control. Expression of tetherin and β-actin in cell lysates and the 
presence of tetherin in culture supernatants were analyzed by Western blot. Similar results 
were obtained in three separate experiments. (B) The experiment was carried out as described 
for panel (A) but supernatants were treated with PNGase F before analysis by Western 
blotting. VLP, virus-like particle; Sups, supernatants. 
 
FIG 4 TMPRSS2 and tetherin TMPRSS2 and tetherin colocalize and interact. (A) 293T cells 
were transfected to express the indicated CFP and YFP fusion proteins alone or in 
combination and subcellular localization was investigated by confocal spinning disc 
microscopy. The scale bar indicates a distance of 10 µm. (B) FACS-FRET analysis of 293T 
cells transfected to express the indicated CFP and YFP fusion proteins. Mean values and SD 
were derived from 3 to 6 independent transfections. Statistical significance was calculated 
using two-tailed students t-test. 
 
FIG 5 Endogenous expression of tetherin and TMPRSS2 determines the efficiency of HIV-1 
release from Caco-2 cells. Caco-2 cells were cotransfected with plasmids encoding HIV-1 
NL4-3 wt or HIV-1 NL4-3 Δvpu and siRNAs targeting tetherin or TMPRSS2. Scrambled 
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siRNA served as negative control (control). The expression of p55-Gag, tetherin and β-actin 
expression in cell lysates and the release of p24-capsid into culture supernatants were 
analyzed by Western blot. Comparable results were obtained in two separate experiments. 
Sups, supernatants. 
 
FIG 6 TMPRSS2 rescues release of authentic influenza virus from restriction by tetherin. (A) 
Caco-2 cells were cotransfected with a plasmid encoding the NA of the 1918 influenza virus 
and siRNAs targeting tetherin or TMPRSS2. Scrambled siRNA served as negative control 
(control). The expression of NA, tetherin and β-actin in cell lysates and the release of NA into 
culture supernatants were analyzed by Western blot. Similar results were obtained in a 
separate experiment. Sups, supernatants. (B) 293T cells were transfected with plasmid 
encoding tetherin or transfected with empty plasmid (control) and infected with influenza 
viruses A/PR/8/34 (H1N1) and A/Panama/2007/99 (H3N2) at MOIs of 0.1 and 0.3, 
respectively. The cells were washed, cultured and at 24 h post infection the presence of 
infectious units in culture supernatants was determined by focus formation assay. The results 
of a representative experiment performed with sextuplicate samples are shown; errors bars 
indicate standard deviation (SD). The results were confirmed in two separate experiments. 
(C) The experiment was carried out as described for panel (B) but target cells were 
transfected with plasmids encoding tetherin wt or tetherin lacking the transmembrane domain 
(ΔTM) and subsequently infected with A/PR/8/34 (H1N1). The results of a representative 
experiment performed with sextuplicate samples are shown; errors bars indicate SD. Similar 
results were obtained in a separate experiment. (D) The experiment was carried out as 
described for panel (C) but 293T cells were transfected with plasmids encoding TMPRSS2 
wt or enzymatically inactive TMPRSS2 (TMPRSS2 mut) in the presence and absence of 
tetherin expression plasmid followed by infection with A/PR/8/34 (H1N1). The presence of 
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infectious units in culture supernatants was determined at 8 h post infection. The results of a 
representative experiment performed with sextuplicate samples are shown; errors bars 
indicate SD. A separate experiment yielded comparable results. (E) Caco2 cells were 
transfected with siRNA specific for tetherin or TMPRSS2 or transfected with scrambled, 
non-sense siRNA (control) and subsequently infected with A/PR/8/34 at an MOI of 0.01. 
Virus titers in culture supernatants were determined at 24 h post infection. The results of a 
single representative experiment performed with triplicate samples are shown and were 
confirmed in three separate experiments. Error bars indicate SD. Statistical significance was 
calculated using two-tailed student’s t-test. 
 
FIG 7 Tetherin and TMPRSS2 are coexpressed in human bronchial cells. Human bronchial 
tissue segments were stained with antibodies directed against TMPRSS2 (red), Tetherin 
(green), β-Tubulin (ciliated cells; magenta) and with DAPI (cell nucleus; cyan) to determine 
the tetherin distribution. The result of a representative confocal image of 5 random selected 
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5. Discussion 
5.1 Novel activators of influenza virus hemagglutinin 
 The human type II transmembrane serine protease family contains 19 members, which 
are expressed in the respiratory tract, the target for influenza virus, and other tissues (Antalis 
et al., 2011). At the beginning of this study, it was known that TMPRSS2, HAT, TMPRSS4 
and matriptase can cleave and activate HA, at least upon directed expression (Baron et al., 
2013; Beaulieu et al., 2013; Böttcher et al., 2006; Chaipan et al., 2009; Hamilton et al., 
2012a), while hepsin was found to cleave but not activate FLUAV HA (Bertram et al., 
2010a). In contrast, TMPRSS3, TMPRSS5 and TMPRSS6 were reported to be unable to 
process HA (Bertram et al., 2010a). The ability of the remaining 12 TTSPs to activate HA 
was unknown. The results reported in manuscript 1 ‘DESC1 and MSPL activate influenza A 
viruses and emerging coronaviruses for host cell entry’, Zmora et al., J Virol, 2014, 
demonstrate that the TTSPs DESC1 and MSPL cleave HA and that cleavage results in HA 
activation.  
 DESC1 (differentially expressed in squamous cell carcinoma 1) is expressed in 
prostate, skin, testis, head, neck, kidney and esophagus, while expression is downregulated in 
some squamous cell carcinomas (Hobson et al., 2004; Lang and Schuller, 2001; Sedghizadeh 
et al., 2006; Uhlen et al., 2015). The present study demonstrates that a small amount of Desc1 
mRNA is expressed in human lung, confirming observations reported by Sales et al. (Sales et 
al., 2011). Additionally, immunohistochemistry revealed that DESC1 protein is present in the 
plasma membrane of cells in renal glomeruli and in squamous epithelium of the esophagus 
and the uterine cervix (Uhlen et al., 2015). The physiological function of DESC1 is not 
known (Antalis et al., 2011). Proteomic Identification of protease Cleavage Sites (PICS) 
which analyses proteome-derived peptide libraries showed that DESC1 prefers large 
hydrophobic residues in P4/P3, small residues in P2, Arg or Lys in P1 and hydrophobic 
residues in P1’ and P3’ (Barre et al., 2014) and this preference is compatible with the 
cleavage motif in the influenza virus HA.  
MSPL (mosaic serine protease long-form) is expressed at low level in the lung, 
placenta and pancreas, and normal prostate shows strong cytoplasmic staining (Guipponi et 
al., 2008b; Kido and Okumura, 2008; Uhlen et al., 2015). The present study confirmed that 
Mspl mRNA is expressed in the human lung but at lower levels compared to Tmprss2 
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transcripts. This enzyme preferentially recognizes cleavage sites consisting of paired basic 
amino acid residues, i.e. arginine or lysine, and is strongly inhibited by serine protease 
inhibitors like aprotinin, banzamidine and Bowman-Birk trypsin inhibitor, but shows some 
resistance to α-1-antitrypsin and leupeptin (Kido and Okumura, 2008). Recently, it was 
demonstrated that Mspl-deficient mice displayed abnormal skin development which resulted 
in a compromised barrier function (Madsen et al., 2014). Thus, MSPL seems to contribute to 
stratum corneum formation and epidermal barrier acquisition (Madsen et al., 2014).  
Additionally, it was observed that MSPL supports avian influenza virus replication by 
proteolytic activation of HA (Okumura et al., 2010), which confirms and extends the 
observations reported in manuscript 1.  
 The observation that absence of TMPRSS2 expression protects mice only partially 
against H3N2 infection and pathogenesis suggests that some FLUAV might be able to 
proteases other than TMPRSS2 for spread in the host and members of the TTSP family are 
interesting candidates (Sakai et al., 2015). However, assessing the contribution of DESC1 and 
MSPL to FLUAV spread in the host will be challenging. Thus, there are no cell lines 
described to express endogenous DESC1 or MSPL at the protein level precluding 
experiments assessing whether these proteases can activate FLUAV upon endogenous 
expression. Moreover, there are no Desc1-deficient mice, which could be employed to 
analyze the contribution of this protease to viral spread in vivo. Mspl-deficient mice were 
reported (Madsen et al., 2014) and were found to display aberrant skin development (Madsen 
et al., 2014). Therefore, it might be difficult to discern direct antiviral effects associated with 
loss of MSPL expression from indirect effects due to tissue malformation. 
In Manuscript 1, TMPRSS11F, prostasin, TMPRSS11B, TMPRSS10 and TMPRSS9 
were found to be unable to activate HA. All proteins were expressed in transiently transfected 
293T cells, although significant differences in expression levels were found. Therefore, it 
cannot be excluded that absence of HA activation by the above mentioned proteases was due 
to insufficient expression. In contrast, failure of HA cleavage was not due to lack of 
autocatalytic activation, since products of autocatalytic activation were detected for all 
proteases investigated. Despite the fact that TMPRSS11F, prostasin and TMPRSS11B were 
cloned from the human lung mRNA during the studies described in manuscript 1, the 
expression of these enzymes in other organs is more prominent. Thus, TMPRSS11F and 
TMPRSS11B are mostly expressed in the gastrointestinal tract, while prostasin can be found 
in skeletal muscles and testis (Uhlen et al., 2015). Therefore, it cannot be excluded that the 
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activity of these three proteases is restricted to different organs, and thus the HA is not 
processed by them. 
Three TTSPs, enteropeptidase, matriptase-3 and TMPRSS11A, were not examined in 
manuscript 1 due to low or absent expression in the human lung (Uhlen et al., 2015). Thus, 
these enzymes remain to be tested for HA activation and these experiments are ongoing. 
TMPRSS11A is an interesting candidate for HA activation, since this enzyme was shown to 
cleave recombinant native trimers of the S protein of SARS-CoV (Kam et al., 2009). The  
S protein of SARS-CoV and MERS-CoV can be activated by both the endosomal cysteine 
proteases cathepsin B/L and TMPRSS2 as well other TTSPs (Simmons et al., 2013), and 
serine protease activity was shown to be essential for viral spread in a rodent model (Zhou et 
al., 2015). Moreover, TMPRSS11a is expressed in the upper respiratory tract (Uhlen et al., 
2015) and could thus support viral spread in the host. The question why some TTSPs (e.g. 
TMPRSS2, MSPL, HAT and DESC1) can cleave HA, while others cannot (e.g. TMPRSS3, 
TMPRSS11F, prostasin), remains open and will be discussed below. 
5.2 Determinants of HA cleavage 
The observation that TMPRSS2 and other TTSPs can active HA in cell culture (Baron 
et al., 2013; Beaulieu et al., 2013; Böttcher et al., 2006; Chaipan et al., 2009; Hamilton et al., 
2012a) raised the question why other members of the TTSP family fail to do so, despite 
efficient expression in transfected cells. Manuscript 2 ‘The stem domain of type II 
transmembrane serine proteases determines the activation of viral glycoproteins and is  
a potential target for intervention’ Zmora et al., J Virol submitted, reports efforts to identify 
which domain(s) in TTSPs control the ability to activate HA. For this purpose, chimeras 
between TMPRSS2, which was previously demonstrated to cleave and activate HA (Böttcher 
et al., 2006), and TMPRSS3, a closely related protease which fails to activate HA (Bertram et 
al., 2010a), were constructed. The exchange of the cytoplasmic domain or the cytoplasmic 
jointly with the transmembrane domain did not alter HA activation (or lack thereof). In 
contrast, replacement of the TMPRSS2 cytoplasmic, transmembrane and stem region by that 
of TMPRSS3 (chimera 3-3-3-2) abrogated HA activation while the reverse changed endowed 
TMPRSS3 with the ability to cleave and activate HA (chimera 2-2-2-3). In addition, the 
replacement of the TMPRSS3 stem region by that of TMPRSS2 conferred HA activation to 
the chimeric enzyme and a similar observation was made with TMPRSS3 (inactive) 
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harboring the stem region of TMPRSS4 (active). Thus, the stem region is the central 
determinant of HA activation.  
A role of the stem region in the recognition and processing of physiological substrates 
was also demonstrated by others. Knappe and colleagues found that frizzled 1 domain and 
LDLR repeats 1–4, the structural elements of stem region of corin, are required for 
processing of the substrate pro-ANP (Knappe et al., 2004). By construction of soluble corin 
consisted only of the catalytic domain, it was shown that the stem region is not required for 
processing of small peptide substrates, but is essential for pro-ANP cleavage. These authors 
suggested that stem region is responsible for substrate specificity, because it is involved in 
the direct interaction between corin and pro-ANP (Knappe et al., 2004). Manuscript 2 
indicates that the stem region might impact substrate specificity by controlling the cellular 
localization of TTSPs, as discussed below. 
One of the major determinants of a protein’s function is its subcellular localization 
and the presence of enzyme and substrate in the same location within the cell is required for 
efficient catalysis (van Albada and ten Wolde, 2007). In manuscript 1 it was demonstrated 
that the HA-activating TTSPs TMPRSS2, DESC1 and MSPL colocalize with HA at or near 
the plasma membrane of infected cells, resulting in a Pearson Correlation Coefficient (PCC,  
a measure of colocalization) above 0.7. In contrast, TMPRSS3, which cannot activate HA, 
failed to colocalize with this protein, which is reflected by a PCC below 0.1. It needs to be 
considered that the cellular localization of TTSPs might be dependent on the cell type and the 
expression level, which might have been unnaturally high in the COS-7 cells used in 
manuscript 1, since these cells were transiently transfected to express TTSPs. Nevertheless, 
the findings described above suggest that colocalization of TTSPs with HA is required for 
HA activation and raised the question whether the stem region determines the cellular 
localization of TTSPs. Indeed, the HA-activating chimera (2-2-2-3) was present at the plasma 
membrane and colocalized with HA, while the chimera which failed to activate HA (3-3-3-2) 
also failed to colocalize with HA. These findings suggest that the stem region can determine 
HA activation by controlling the cellular localization of TTSPs. A role of the stem region in 
the cellular trafficking of TTSPs was also suggested in reviews (Antalis et al., 2011; Szabo 
and Bugge, 2011) but data supporting these claims are largely missing.  
 The key role of the stem region in HA activation triggered interest in determining 
whether the stem region can be a target for inhibitors of TTSP activity. Members of the 
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Hepsin/TMPRSS subfamily contain a group A scavenger receptor domain in the stem region, 
which in the context of scavenger receptor type A (SR-A) is responsible for binding of low-
density lipoproteins and for removal of these proteins from the circulation (Canton et al., 
2013). Dextran sulphate is an inhibitor of SR-A (Tsubamoto et al., 1994). Therefore, it was 
tested whether dextran sulphate inhibits HA activation by TTSPs contain an SR domain in 
their stem region. Activation of FLUAV by all TTSPs containing a SR domain was 
significantly inhibited by dextran sulphate, while virus activation by TTSPs not harboring the 
SR domain was not affected. The ability of dextran sulphate to suppress FLUAV spread 
correlated with inhibition of HA cleavage in transfected cells, although the effects observed 
were minor, likely due to high expression of protease and HA in the experimental system 
used. Collectively, these data suggest that targeting the stem region might a suitable way to 
prevent FLUAV activation by TTSPs. However, future studies must provide direct evidence 
that dextran sulphate bound to the SR domain and that binding was required for inhibition of 
HA activation. Additional proof of concept could be provided by raising antibodies against 
the SR domain of TTSPs and by testing their ability to block HA activation. 
 Inhibition of FLUAV activation by dextran sulphate was specific to TTSPs containing 
an SR domain but demonstrates that blockade of these enzymes could be a powerful tool to 
suppress FLUAV spread. This notion is in keeping with several findings indicating that broad 
spectrum protease inhibitors can suppress FLUAV spread in cell culture and in the host 
(Zhirnov et al., 2011). Recently, it was found that also endogenous protease inhibitors can 
block FLUAV spread. Dittmann et al. demonstrated that plasminogen activator inhibitor 1, 
the product of serpine1 gene, can inhibit the proteolytic processing of HA by TMPRSS2 and 
HAT (Dittmann et al., 2015). Additionally, it was observed that FLUAV infection in 
serpine1-/- mice was more severe and lethal (Dittmann et al., 2015). Moreover, the 
hepatocyte growth activator inhibitor 2 (HAI2) was found to inhibit HA activation in cell 
culture (Hamilton et al., 2014). Whether the inhibitory effect of these inhibitors extends to all 
HA activating TTSPs is unknown.  
5.3 Different TMPRSS2 isoforms activate HA 
The transcripts encoding TTSPs can be alternatively spliced and this may have 
important consequences for enzymatic activity. Qi et al. demonstrated that the alternative 
splicing of the corin transcript results in the production of two isoforms, E1 and E1a, which 
differ in the presence of an N-terminal extension of 30 amino acids, which alters cellular 
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localization and enzymatic activity (Qi et al., 2011). The Tmprss2 transcript can also be 
alternatively spliced and this results in the generation of isoforms 1 and 2 which differ only in 
the N-terminal cytoplasmic tail (Jacquinet et al., 2001; Paoloni-Giacobino et al., 1997). The 
Tmprss2 transcript variant 1 (encoding TMPRSS2 isoform 1) contains additional 111 
nucleotides, which encode a 37 amino acids comprising N-terminal extension in comparison 
to transcript variant 2 (encoding for TMPRSS2 isoform 2), posing the question whether this 
extension impacts HA activation. The study reported in manuscript 4 ‘TMPRSS2 isoforms 1 
activates respiratory viruses and is expressed in viral target cells’ Zmora et al., PLOS ONE, 
2015, shows that TMPRSS2 isoforms 1 and 2 are comparably expressed in transfected cells 
and demonstrates that potential FLUAV target cells in the human lung express transcript 
variant 1. Moreover, the results show that both isoforms cleave and activate FLUAV and 
colocalize with HA at or near to the plasma membrane. Moreover, the analysis of the  
N-terminal sequence of TMPRSS2 isoform 1 with MmM 3.0 (Minimotif Miner), MotifScan 
and CombFunc Protein Function Prediction Server, Imperial College London, did not detect 
motifs characteristic for endocytosis, intracellular signaling or localization. Therefore, the 
cytoplasmic tail of TMPRSS2 might not impact HA cleavage. However, the analysis of HA 
cleavage and colocalization of isoforms 1 and 2 was carried out with transfected cells and it 
can at present not be excluded that potential differences in expression and function of the 
isoforms were obscured by high expression of these enzymes in the transfected cells. 
5.4 The role of TTSPs in influenza virus release 
Many published studies, including the work discussed above, demonstrate that TTSPs 
can activate viral glycoproteins and thereby play an important role in viral entry (Bertram et 
al., 2010b; Garten et al., 2015). Notably, TTSPs may also contribute to viral release.  Shirato 
and colleagues found that PEDV release was promoted by expression of TMPRSS2 while 
intracellular replication was not affect (Shirato et al., 2011). Thus, large clusters of virions 
were retained at the surface of infected cells which failed to express TMPRSS2 or were 
treated with a serine protease inhibitor, while these structures were not observed when 
TMPRSS2 was expressed (Shirato et al., 2011). These results suggest that TMPRSS2 might 
counteract a cellular factor which interferes with viral release. The IFN-induced host cell 
protein tetherin inhibits release of several enveloped viruses from infected cells (in the 
absence of a virus-encoded tetherin antagonist) and is an important component of the innate 
defenses against viral infection (Neil et al., 2008; Van Damme et al., 2008). Whether FLUAV 
can be inhibited by tetherin was unclear. Some studies demonstrated that FLUAV are tetherin 
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insensitive (Bruce et al., 2012; Watanabe et al., 2011; Winkler et al., 2012), while other 
studies demonstrated tetherin-mediated inhibition of viral release (Leyva-Grado et al., 2014; 
Mangeat et al., 2012). One possibility to account for these discrepant observations is that 
FLUAV inhibition by tetherin might be dependent on the viral strain examined. Therefore, it 
was first tested whether laboratory-adapted, seasonal and pandemic FLUAV differ in tetherin 
sensitivity.  
Manuscript 4 ‘Tetherin sensitivity of influenza A viruses is strain specific: Role of 
hemagglutinin and neuraminidases’, Gnirß, Zmora et al., J Virol, 2015, shows that 
laboratory-adapted and seasonal FLUAV strains are sensitive to inhibition by tetherin while 
pandemic strains are resistant, and resistance was linked to the HA and NA proteins. 
Importantly, these results were confirmed in different experimental systems, including cells 
which exogenously or endogenously express tetherin. However, the mechanism underlying 
tetherin antagonism by HA and NA remained largely unclear, although evidence was 
obtained that tetherin-resistant FLUAV reduce intracellular expression of tetherin 
(manuscript 4). Whether this effect is due to HA/NA induced tetherin degradation and 
whether degradation occurs in endo-/lysosomes or in proteasomes remains to be established. 
Moreover, it will be important to examine a broader panel of FLUAV strains for tetherin 
sensitivity, including strains responsible for all FLUAV pandemics since 1918 as well as 
LPAIV and HPAIV. In sum, the results reported in manuscript 4 show that certain FLUAV 
are tetherin-sensitive and raised the question whether TTSP expression rescues these strains 
from inhibition by tetherin. 
 Manuscript 5 ‘Influenza virus activating host cell proteases antagonize tetherin’ 
Krämer-Kühl, Zmora, Blazejewska and Gnirß
 
et al., J Virol, submitted, demonstrates that 
TTSPs, which cleave and activate HA, TMPRSS2, TMPRSS4, HAT, DESC1 and MSPL, 
also cleave tetherin and rescue FLUAV from tetherin-mediated inhibition. These findings 
suggest that infection of TTSP-positive cells might be associated with two benefits for 
FLUAV, HA activation and tetherin antagonism. A central question which remains to be 
answered is whether tetherin antagonism by TTSPs is operative in vivo. Two observations 
suggest that this might be the case: First, siRNA-mediated knock-down of tetherin expression 
in Caco-2 cells increased FLUAV spread while knock-down of TMPRSS2 expression had the 
opposite effect. Second, tetherin and TMPRSS2 were coexpressed in human respiratory 
epithelium and thus in potential FLUAV target cells. However, increase of viral spread in 
Caco-2 cells upon tetherin knock-down was modest and ultimately animal studies will be 
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required to assess the in vivo relevance of TTSP-mediated tetherin antagonism. The major 
challenge associated with these studies it to discriminate TTSP-mediated augmentation of 
FLUAV spread due to HA activation and tetherin antagonism. 
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7. List of abbreviations 
AIDS  acquired immunodeficiency syndrome 
BST-2  bone marrow stromal cell antigen 2 
CoV  coronavirus 
CUB  Cls/Clr, urchin embryonic growth factor and bone morphogenetic proten-1 
DESC1 differentialy expressed in squamous cell carcinoma 1 
E  glutamic acid 
ER  endoplasmatic reticulum 
F  phenylalanine 
FLUAV influenza A virus 
FLUBV influenza B virus 
FLUCV influenza C virus 
Fz  frizzled domain 
G  glycine 
GPI  glycosyl-phospatidylinositol 
HA  hemagglutinin 
HA1  hemagglutinin 1 subunit 
HA2  hemagglutinin 2 subunit 
HAT  human airway trypsin-like protease 
HIV  human immunodeficiency virus 
HPAIV highly pathogenic avian influenza virus 
K  lysine 
L  leucine 
LDLRA low-density lipoprotein receptor class A domain 
LPAIV low pathogenic avian influenza virus 
M1  matrix 1 protein 
M2  matrix 2 protein 
MAM  meprin, A5 antigen, and receptor protein phosphatase µ domain 
MERS  Middle East respiratory syndrome 
MmM  Minimotif Miner 
MSPL  mosaic serine protease long-form 
N  asparagine  
NA  neuraminidase 
NEP  nuclear export protein 
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NP  nucleoprotein 
NS1  non-structural protein 1 
NS2  non-structural protein 2 
PA  polymerase acidic protein 
PB1  polymerase basic protein 1 
PB2  polymerase basic protein 2 
PCC  Pearson correlation coefficient 
PEDV  porcine epidemic diarrhea virus 
PICS  proteomic identification of protease cleavage sites 
pro-ANP pro-atrial natriuretic peptide 
R  serine 
RNA  ribonucleic acid 
S  spike 
SARS  severe acute respiratory syndrome 
SEA  sea urchin sperm protein/enteropeptidase/agrin 
SR  Group A scavenger receptor domain 
SR-A  scavenger receptor type A 
T  threonine 
TM  transmembrane domain 
TTSP  type II transmembrane serine protease 
USD  United States dollar 
vRNP  viral ribonucleoprotein 
WHO  World Health Organization 
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